{"gene":"F8","run_date":"2026-04-28T17:46:03","timeline":{"discoveries":[{"year":1984,"finding":"The complete mRNA sequence encoding human coagulation factor VIII was cloned and expressed in mammalian cells, revealing a single-chain precursor of 2,351 amino acids (Mr ~267 kDa) with a domain structure showing sequence repeats and structural relatedness to factor V and ceruloplasmin; recombinant protein corrected clotting time in hemophiliac plasma.","method":"cDNA cloning, sequencing, and expression in cultured mammalian cells; functional clotting assay","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 — original molecular cloning with functional validation, foundational study replicated by two independent groups simultaneously","pmids":["6438528","6438526"],"is_preprint":false},{"year":1985,"finding":"Point mutations (nonsense) and partial deletions in the F8 gene were identified as molecular causes of hemophilia A, establishing the heterogeneous mutational basis of the disease.","method":"Southern blotting and direct sequencing of F8 gene in 92 hemophilia A patients","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 — direct sequencing with functional correlation; foundational study, widely replicated","pmids":["2987704"],"is_preprint":false},{"year":1988,"finding":"The FVIII light chain (80 kDa), but not the heavy chain, binds to von Willebrand factor (vWF) with a stoichiometry of one light chain per vWF subunit; thrombin cleavage removing an acidic 41-residue N-terminal peptide from the light chain completely abolishes vWF binding, and intact FVIII bound to vWF is fully released after thrombin proteolysis.","method":"Analytical velocity sedimentation of purified porcine FVIII chains with multimeric vWF; thrombin proteolysis experiments","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution with purified components, quantitative binding stoichiometry established","pmids":["3134349"],"is_preprint":false},{"year":1991,"finding":"Sulfation of Tyr1680 in the acidic region of the FVIII light chain is essential for interaction with vWF; site-directed mutagenesis replacing Tyr1680 with Phe completely abolished vWF binding, and expression in the presence of chlorate (sulfation inhibitor) also abrogated binding.","method":"Site-directed mutagenesis, expression in COS-1 cells, vWF binding assay, cell-free sulfation studies with tyrosylprotein sulfotransferase","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — mutagenesis combined with biochemical binding assay and enzymatic sulfation study; multiple orthogonal methods in single study","pmids":["1898735"],"is_preprint":false},{"year":1991,"finding":"Activated protein C (APC) inactivates factor VIII and factor VIIIa by proteolytic cleavage within the heavy chain at Arg336 and Arg562 (and proposed Arg740); cleavage at Arg562 most closely correlates with loss of cofactor activity and promotes dissociation of the A2 domain from the A1/light chain dimer.","method":"In vitro proteolysis of purified human FVIII/FVIIIa with APC, NH2-terminal sequencing of cleavage fragments, anti-A2 monoclonal antibody reactivity, gel filtration analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution with purified components, direct N-terminal sequencing of cleavage sites, multiple orthogonal methods","pmids":["1939075"],"is_preprint":false},{"year":1993,"finding":"Inversions disrupting the factor VIII gene, resulting from intrachromosomal recombination between a homologous sequence in intron 22 (int22h) and upstream copies of that sequence, account for approximately 45% of severe hemophilia A cases.","method":"Southern blot assay detecting inversion-specific restriction fragment patterns in hemophilia A patient cohorts","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 — direct molecular detection in large patient cohort; independently replicated as the most common severe HA mutation","pmids":["8275087"],"is_preprint":false},{"year":1997,"finding":"Both the acidic region (residues 1649–1689, including sulfated Tyr1680) and the C2 domain of the FVIII light chain are directly involved in forming the high-affinity vWF-binding site; the acidic region is also required to maintain the optimal conformation of the vWF-binding site within C2.","method":"Limited V8 protease digestion of FVIII light chain to generate defined fragments; surface plasmon resonance binding measurements; anti-C2 and anti-acidic region monoclonal antibody assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — quantitative binding kinetics with purified fragments by SPR, multiple truncation mutants tested","pmids":["9218428"],"is_preprint":false},{"year":1998,"finding":"FVIII circulates as a metal ion-dependent heterodimer of heavy chain and light chain; activation by thrombin or factor Xa involves limited proteolysis at three sites yielding factor VIIIa, which dramatically increases the catalytic efficiency of factor IXa in activating factor X primarily by increasing kcat.","method":"Biochemical characterization review synthesizing in vitro proteolysis, activity assays, and structural data","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1 — synthesis of multiple reconstitution studies; established mechanistic framework","pmids":["9834200"],"is_preprint":false},{"year":2003,"finding":"Mutations in MCFD2, an EF-hand domain protein that forms a calcium-dependent heteromeric complex with LMAN1 in the ERGIC, cause combined FV and FVIII deficiency (F5F8D), establishing that the LMAN1-MCFD2 complex functions as a cargo receptor for ER-to-Golgi transport of both FV and FVIII.","method":"Patient mutation analysis, subcellular co-localization, co-immunoprecipitation demonstrating calcium-dependent MCFD2-LMAN1 interaction, yeast two-hybrid","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 — reciprocal co-IP, patient genetics, and functional secretion assays; independently replicated","pmids":["12717434"],"is_preprint":false},{"year":2004,"finding":"Factor VIIIa acts as a cofactor by markedly increasing the catalytic rate constant (kcat) of factor IXa for factor X activation; thrombin or factor Xa activate FVIII by cleaving at three defined sites in the heavy chain (Arg372, Arg740) and light chain (Arg1689), altering covalent structure and conformation.","method":"In vitro proteolysis with thrombin/FXa, kinetic assays of FIXa/FVIIIa complex activity, fragment characterization","journal":"Blood reviews","confidence":"High","confidence_rationale":"Tier 1 — mechanistic review synthesizing multiple in vitro reconstitution studies with defined cleavage site mapping","pmids":["14684146"],"is_preprint":false},{"year":2008,"finding":"X-ray crystal structure of B domain-deleted human factor VIII revealed five globular domains with one Ca2+ and two Cu2+ ions; A1 and A3 domains form the base of a triangular A-domain heterotrimer; C1 and C2 domains contain membrane-binding features; in silico docking with factor IXa suggested an extended interface spanning both heavy and light chains of FVIII.","method":"X-ray crystallography (crystal structure determination) of BDD-FVIII; in silico docking modeling with factor IXa based on biochemical constraints","journal":"Structure","confidence":"High","confidence_rationale":"Tier 1 — crystal structure with functional modeling; single rigorous structural study","pmids":["18400180"],"is_preprint":false},{"year":2009,"finding":"The LMAN1-MCFD2 complex serves as a cargo receptor for ER-to-Golgi transport of FV and FVIII; MCFD2 missense mutations in EF-hand domains abolish the calcium-dependent interaction with LMAN1; the B domain of FVIII may be important in mediating its interaction with the LMAN1-MCFD2 complex.","method":"Patient mutation analysis in F5F8D, biochemical characterization of MCFD2-LMAN1 interaction, review of functional studies","journal":"British journal of haematology","confidence":"High","confidence_rationale":"Tier 2 — patient genetics combined with biochemical binding data; independently replicated across multiple labs","pmids":["19183188"],"is_preprint":false},{"year":2011,"finding":"LMAN1-deficient mice show ~50% reduction in plasma FV and FVIII and platelet FV, confirming the ER-to-Golgi cargo receptor role of the LMAN1-MCFD2 complex for FV and FVIII; ER in Lman1-/- hepatocytes is distended with accumulation of α1-antitrypsin and GRP78, indicating ER stress.","method":"Mouse knockout model (Lman1-/- mice), plasma factor activity assays, electron microscopy, immunohistochemistry, in vitro COPII vesicle formation assay","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — clean knockout with specific phenotypic readout and multiple orthogonal assays","pmids":["21795745"],"is_preprint":false},{"year":2013,"finding":"Human mesenchymal stem cells (MSC) from lung, liver, brain, and bone marrow express FVIII mRNA and secrete functional FVIII protein; in MSC, FVIII localizes to the perinuclear region rather than being stored in granules, in contrast to endothelial cells.","method":"Quantitative RT-PCR, confocal microscopy with FVIII-specific antibody, aPTT and chromogenic functional assays of MSC supernatants and lysates","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 2 — direct localization with functional confirmation; single lab study","pmids":["23042590"],"is_preprint":false},{"year":2006,"finding":"Regulated secretion of both VWF and FVIII from endothelial storage granules (Weibel-Palade bodies) occurs only when there is endogenous co-synthesis of FVIII together with VWF; VWF serves as the carrier protecting FVIII from proteolytic degradation in plasma.","method":"DDAVP stimulation experiments, cell biology studies of VWF/FVIII co-expression and co-storage","journal":"Pediatric blood & cancer","confidence":"Medium","confidence_rationale":"Tier 2 — functional co-secretion experiments with defined cellular readout; moderate evidence base","pmids":["16470522"],"is_preprint":false},{"year":2016,"finding":"VWF inhibits uptake of FVIII by immature dendritic cells and activation of FVIII-specific T cells in a dose-dependent manner; recombinant VWF lacking the FVIII-binding domain did not inhibit T-cell activation, indicating that VWF reduces FVIII immunogenicity by shielding it from antigen-presenting cells through direct binding.","method":"In vitro dendritic cell uptake assay, T-cell activation assay with VWF and VWF mutant lacking FVIII-binding domain","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 — functional assay with domain-deletion controls establishing mechanistic link; single lab","pmids":["27587878"],"is_preprint":false},{"year":2019,"finding":"miR-374b-5p and miR-30c-5p target the 3'UTR of F8 mRNA; overexpression of these miRNAs in cell lines constitutively expressing FVIII decreased FVIII expression, while an miR-30c-5p inhibitor partially restored FVIII expression, establishing a miRNA-based mechanism for F8 gene regulation.","method":"miRNA sequencing, overexpression of miRNAs in FVIII-expressing cell lines, miRNA inhibitor experiments, FVIII activity assay","journal":"Transfusion","confidence":"Medium","confidence_rationale":"Tier 2 — gain- and loss-of-function experiments with functional readout; single lab, moderate study size","pmids":["31785023"],"is_preprint":false},{"year":2020,"finding":"miR-19b-3p and miR-186-5p directly interact with F8 mRNA (identified by RNA-affinity purification) and suppress FVIII protein levels when overexpressed in mammalian cells, providing further evidence that miRNAs targeting the F8 3'UTR can modulate FVIII production.","method":"In vivo RNA-affinity purification, miRNA overexpression in mammalian cells, FVIII activity measurement","journal":"Frontiers in cell and developmental biology","confidence":"Medium","confidence_rationale":"Tier 2 — direct RNA-affinity purification plus functional overexpression assay; single lab","pmids":["32850803"],"is_preprint":false},{"year":2023,"finding":"LMAN1 primarily serves as a shuttling carrier for MCFD2, while MCFD2 carries out the actual cargo binding and transport of FV and FVIII; LMAN1 carbohydrate-binding activity is not essential for FV/FVIII transport; overexpression of MCFD2 alone is sufficient to rescue FV/FVIII secretion in LMAN1-deficient cells; the LMAN1-MCFD2 complex is not rate-limiting for ER-Golgi transport of FV/FVIII.","method":"LMAN1- and MCFD2-deficient cell lines (HEK293T, HepG2, HCT116), FV/FVIII secretion assays, rescue experiments with wild-type and mutant LMAN1/MCFD2 overexpression","journal":"Blood advances","confidence":"High","confidence_rationale":"Tier 1 — multiple cell-type knockouts with rescue experiments and mutant analysis; mechanistic dissection with orthogonal approaches","pmids":["36490287"],"is_preprint":false},{"year":2021,"finding":"Immune tolerance against FVIII is maintained by PD-L1-expressing regulatory T cells (Tregs) that ligate PD-1 on FVIII-specific B cells causing their apoptosis; FVIII-deficient mice lack such Tregs and develop inhibitors; repetitive FVIII injection (ITI) induces FVIII-specific PD-L1+ Tregs and re-engages B cell elimination; FVIII-specific Tregs exist in humans and upregulate PD-L1 after successful ITI.","method":"Mouse knockout model, flow cytometry, ITI mouse model, human patient samples, PD-1/PD-L1 blockade experiments, B cell apoptosis assays","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods in mouse and human, mechanistic pathway established with specific cellular readouts","pmids":["36107620"],"is_preprint":false},{"year":2021,"finding":"A 23.4-kb tandem duplication of the proximal F8 gene (promoter, exon 1, and part of intron 1) causes markedly elevated FVIII levels (>400%) and familial thrombophilia; the duplication produces twofold upregulation of F8 mRNA; a 927-bp region within the duplicated F8 intron 1 contains an enhancer element driving >45-fold increased reporter activity in endothelial cells.","method":"Genetic analysis, quantitative RT-PCR, luciferase reporter assay in endothelial cells, chromatin accessibility analysis","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1–2 — reporter assay with functional validation of enhancer element, corroborated by patient genetics and RNA quantification","pmids":["33275657"],"is_preprint":false},{"year":2016,"finding":"A single immunodominant HLA-DRA*01-DRB1*01:01-restricted epitope in FVIII (peptide 2194–2213, C2 domain) is recognized by CD4+ T-effector cells from both severe and mild hemophilia A subjects with inhibitors; high-avidity T-cell clones from multiple subjects share the same T-cell receptor beta (TCRB) gene, indicating a remarkably narrow TCR repertoire driving inhibitor responses.","method":"MHC class II tetramer staining, T-cell clone isolation, cytokine secretion assays, TCRB gene sequencing, high-throughput immunosequencing","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal immune assays including tetramers, clonal T-cell analysis, and high-throughput sequencing","pmids":["27471234"],"is_preprint":false},{"year":2018,"finding":"Amino acid substitution F2196A or M2199A within the immunodominant FVIII C2-domain epitope (residues 2194–2205) abrogates HLA-DRB1*01:01-restricted T-cell proliferation while retaining normal procoagulant activity and expression levels, establishing these residues as critical for MHC class II binding and T-cell recognition.","method":"Peptide-MHCII binding assays, T-cell proliferation assays with clones and polyclonal lines, production of recombinant BDD-FVIII mutant proteins with FVIII activity measurement","journal":"Blood advances","confidence":"High","confidence_rationale":"Tier 1 — mutagenesis combined with functional MHCII binding, T-cell assay, and procoagulant activity measurement","pmids":["29444872"],"is_preprint":false},{"year":2010,"finding":"A point mutation causing Leu176Pro substitution in the A1 domain of rat FVIII (F8 gene, autosomal chromosome 18 in rats) disrupts the tertiary structure of FVIII and causes hemophilia A-like FVIII deficiency; the defect is corrected by human plasma or recombinant human FVIII administration.","method":"F8 cDNA sequencing, coagulation factor activity assays, structural prediction, human FVIII replacement experiment in WAG/RijYcb rats","journal":"Journal of thrombosis and haemostasis","confidence":"Medium","confidence_rationale":"Tier 2 — mutation identification with functional rescue; single study in a novel rat model","pmids":["20626616"],"is_preprint":false}],"current_model":"Factor VIII (F8) is a procofactor in blood coagulation that circulates as a metal ion-dependent (Ca2+, Cu2+) heterodimer of heavy and light chains in a noncovalent complex with von Willebrand factor (vWF); vWF binding requires sulfation of Tyr1680 and both the acidic region and C2 domain of the FVIII light chain, and protects FVIII from degradation; thrombin or factor Xa activate FVIII by cleaving at three defined sites (Arg372, Arg740 in heavy chain; Arg1689 in light chain) releasing it from vWF and generating factor VIIIa, which dramatically increases factor IXa catalytic efficiency (kcat) for factor X activation in the intrinsic tenase complex; APC inactivates FVIIIa by cleavage at Arg336 and Arg562 with consequent A2 domain dissociation; ER-to-Golgi secretion of FVIII requires the LMAN1-MCFD2 cargo receptor complex (MCFD2 mediates cargo binding while LMAN1 serves as the shuttling carrier); intron 22 inversions account for ~45% of severe hemophilia A; immune tolerance to FVIII is maintained by PD-L1+ regulatory T cells eliminating FVIII-specific B cells via PD-1 ligation; and miRNAs targeting the F8 3'UTR (including miR-374b-5p, miR-30c-5p, miR-19b-3p, miR-186-5p) can fine-tune FVIII protein levels."},"narrative":{"teleology":[{"year":1984,"claim":"Cloning the full-length F8 cDNA resolved the primary structure, domain architecture, and homology to factor V and ceruloplasmin, establishing the molecular identity of the coagulation cofactor and enabling recombinant expression that corrected hemophiliac plasma clotting.","evidence":"cDNA cloning, sequencing, and expression in mammalian cells with functional clotting assay","pmids":["6438528","6438526"],"confidence":"High","gaps":["B domain function remained unclear","post-translational processing pathway not yet defined"]},{"year":1985,"claim":"Identification of point mutations and deletions in the F8 gene as causes of hemophilia A established the heterogeneous mutational basis of the disease and linked genotype to phenotype.","evidence":"Southern blotting and direct sequencing in 92 hemophilia A patients","pmids":["2987704"],"confidence":"High","gaps":["most common severe mutation (intron 22 inversion) not yet discovered","genotype–phenotype correlations incomplete"]},{"year":1991,"claim":"Defining the vWF-binding determinants on the FVIII light chain—particularly the essential role of sulfated Tyr1680 in the acidic region—and the APC inactivation sites (Arg336, Arg562) established the principal regulatory switches controlling FVIII stability and shutdown.","evidence":"Site-directed mutagenesis with COS-1 expression, vWF binding assays, and in vitro APC proteolysis with N-terminal sequencing of fragments","pmids":["1898735","1939075","3134349"],"confidence":"High","gaps":["structural basis of A2 domain dissociation not determined","relative contribution of C2 domain to vWF binding not yet quantified"]},{"year":1993,"claim":"Discovery that intrachromosomal inversions at intron 22 account for ~45% of severe hemophilia A identified the single most common causative mutation and transformed molecular diagnostics.","evidence":"Southern blot detection of inversion-specific restriction patterns in hemophilia A cohorts","pmids":["8275087"],"confidence":"High","gaps":["mechanism favoring inversion in male meiosis not fully elucidated","intron 1 inversions not yet characterized"]},{"year":1997,"claim":"Demonstrating that both the acidic region and C2 domain contribute to high-affinity vWF binding refined the two-site model for the FVIII–vWF interaction.","evidence":"SPR binding kinetics of defined FVIII light chain fragments with vWF, monoclonal antibody competition","pmids":["9218428"],"confidence":"High","gaps":["atomic-resolution structure of the FVIII–vWF interface not determined"]},{"year":1998,"claim":"Kinetic characterization established that FVIIIa increases factor IXa activity primarily by elevating kcat rather than Km for factor X, defining the cofactor mechanism within the tenase complex.","evidence":"In vitro kinetic analysis of reconstituted tenase complex","pmids":["9834200"],"confidence":"High","gaps":["structural basis of kcat enhancement by FVIIIa not resolved","role of membrane surface in cofactor function incompletely defined"]},{"year":2003,"claim":"Identification of MCFD2 mutations in combined FV/FVIII deficiency patients revealed that the LMAN1–MCFD2 complex functions as the ER-to-Golgi cargo receptor for FVIII (and FV), solving the secretion pathway question.","evidence":"Patient mutation analysis, co-immunoprecipitation, yeast two-hybrid, subcellular co-localization","pmids":["12717434"],"confidence":"High","gaps":["relative contributions of LMAN1 vs MCFD2 to cargo binding not dissected","whether the complex is rate-limiting for secretion unknown"]},{"year":2008,"claim":"The X-ray crystal structure of B domain-deleted FVIII revealed the spatial arrangement of the five domains with bound Ca²⁺ and Cu²⁺ ions, and in silico docking provided the first model of the FVIIIa–FIXa interface.","evidence":"X-ray crystallography of BDD-FVIII, computational docking with FIXa","pmids":["18400180"],"confidence":"High","gaps":["no experimental structure of the FVIIIa–FIXa complex","conformational changes upon thrombin activation not captured"]},{"year":2016,"claim":"Identification of an immunodominant HLA-DRB1*01:01-restricted T-cell epitope in the FVIII C2 domain (residues 2194–2213) with a remarkably narrow TCR repertoire explained a key driver of inhibitor development, and subsequent mutagenesis showed that F2196A and M2199A abolish T-cell recognition while preserving procoagulant activity.","evidence":"MHC class II tetramer staining, T-cell cloning, TCR sequencing, peptide–MHCII binding assays, recombinant FVIII mutagenesis with activity measurement","pmids":["27471234","29444872"],"confidence":"High","gaps":["whether deimmunized FVIII variants are tolerated long-term in vivo not tested","epitopes restricted by other HLA alleles not fully mapped"]},{"year":2019,"claim":"Discovery that miRNAs (miR-374b-5p, miR-30c-5p, miR-19b-3p, miR-186-5p) target the F8 3′UTR and suppress FVIII production established a post-transcriptional regulatory layer for F8 gene expression.","evidence":"miRNA sequencing, gain- and loss-of-function experiments in FVIII-expressing cell lines, RNA-affinity purification","pmids":["31785023","32850803"],"confidence":"Medium","gaps":["physiological relevance of miRNA-mediated regulation of endogenous FVIII levels not demonstrated in vivo","no reporter assay confirming direct 3′UTR interaction for all four miRNAs"]},{"year":2021,"claim":"Demonstration that PD-L1⁺ Tregs eliminate FVIII-specific B cells via PD-1 ligation revealed the cellular mechanism maintaining peripheral tolerance to FVIII and explained why immune tolerance induction (ITI) can resolve inhibitors.","evidence":"Mouse knockout and ITI models, human patient samples, PD-1/PD-L1 blockade, B cell apoptosis assays, flow cytometry","pmids":["36107620"],"confidence":"High","gaps":["whether PD-L1+ Treg mechanism applies across all HLA backgrounds not established","signals driving PD-L1 upregulation on Tregs during ITI not identified"]},{"year":2021,"claim":"Identification of an endothelial-specific enhancer element within F8 intron 1 that drives markedly elevated FVIII levels when duplicated provided the first cis-regulatory explanation for familial thrombophilia due to FVIII excess.","evidence":"Genetic analysis of familial thrombophilia, quantitative RT-PCR, luciferase reporter assay in endothelial cells","pmids":["33275657"],"confidence":"High","gaps":["transcription factors binding the enhancer element not identified","chromatin context of enhancer activity in non-endothelial cells not explored"]},{"year":2023,"claim":"Mechanistic dissection of the LMAN1–MCFD2 complex showed that MCFD2 performs direct cargo binding while LMAN1 serves as the cycling carrier, and that this complex is not rate-limiting for FVIII secretion, revising the earlier model.","evidence":"LMAN1- and MCFD2-deficient cell lines with rescue experiments and mutant LMAN1/MCFD2 overexpression across HEK293T, HepG2, and HCT116 cells","pmids":["36490287"],"confidence":"High","gaps":["identity of the rate-limiting step in FVIII ER-to-Golgi transport remains unknown","structural basis of MCFD2–FVIII interaction not determined"]},{"year":null,"claim":"Key unresolved questions include the atomic-resolution structure of the FVIIIa–FIXa tenase complex, the identity of transcription factors binding the intron 1 enhancer, the in vivo physiological relevance of miRNA regulation of FVIII levels, and whether deimmunized FVIII variants can achieve long-term tolerance in patients.","evidence":"","pmids":[],"confidence":"Low","gaps":["no experimental FVIIIa–FIXa co-crystal or cryo-EM structure","cis-regulatory architecture of the F8 locus incompletely defined","clinical translation of deimmunized FVIII not tested"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[7,9,10]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[10]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,2,7,14]},{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[8,11,12,18]},{"term_id":"GO:0005794","term_label":"Golgi apparatus","supporting_discovery_ids":[8,11,18]},{"term_id":"GO:0031410","term_label":"cytoplasmic vesicle","supporting_discovery_ids":[14]}],"pathway":[{"term_id":"R-HSA-109582","term_label":"Hemostasis","supporting_discovery_ids":[0,4,7,9,10]},{"term_id":"R-HSA-9609507","term_label":"Protein localization","supporting_discovery_ids":[8,11,12,18]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[19,21,22]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[1,5,23]}],"complexes":["intrinsic tenase complex (FVIIIa–FIXa–FX)","FVIII–vWF complex"],"partners":["VWF","F9","F10","LMAN1","MCFD2","PROC"],"other_free_text":[]},"mechanistic_narrative":"Factor VIII (F8) is a plasma glycoprotein procofactor essential for the intrinsic pathway of blood coagulation, serving as the critical cofactor that dramatically increases the catalytic efficiency (kcat) of factor IXa for factor X activation within the intrinsic tenase complex [PMID:9834200, PMID:14684146]. FVIII circulates as a metal ion-dependent (Ca²⁺, Cu²⁺) heterodimer of heavy and light chains in a noncovalent complex with von Willebrand factor (vWF), which binds via the sulfated Tyr1680 residue and the C2 domain of the FVIII light chain and protects FVIII from proteolytic degradation and immune uptake [PMID:3134349, PMID:1898735, PMID:9218428, PMID:27587878]; thrombin or factor Xa activate FVIII by cleaving at Arg372, Arg740, and Arg1689, releasing it from vWF, while activated protein C inactivates FVIIIa by cleavage at Arg336 and Arg562 with consequent A2 domain dissociation [PMID:14684146, PMID:1939075]. ER-to-Golgi secretion of FVIII requires the LMAN1–MCFD2 cargo receptor complex, in which MCFD2 mediates direct cargo binding while LMAN1 serves as the shuttling carrier [PMID:12717434, PMID:36490287]. Loss-of-function mutations in F8—including intron 22 inversions accounting for ~45% of severe cases—cause hemophilia A, while immune tolerance to therapeutic FVIII is maintained by PD-L1⁺ regulatory T cells that eliminate FVIII-specific B cells via PD-1 ligation [PMID:8275087, PMID:36107620]."},"prefetch_data":{"uniprot":{"accession":"P00451","full_name":"Coagulation factor VIII","aliases":["Antihemophilic factor","AHF","Procoagulant component"],"length_aa":2351,"mass_kda":267.0,"function":"Factor VIII, along with calcium and phospholipid, acts as a cofactor for F9/factor IXa when it converts F10/factor X to the activated form, factor Xa","subcellular_location":"Secreted, extracellular space","url":"https://www.uniprot.org/uniprotkb/P00451/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/F8","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/F8","total_profiled":1310},"omim":[{"mim_id":"621535","title":"SPINOCEREBELLAR ATAXIA 52; SCA52","url":"https://www.omim.org/entry/621535"},{"mim_id":"621143","title":"HOLOPROSENCEPHALY 10; HPE10","url":"https://www.omim.org/entry/621143"},{"mim_id":"620865","title":"EHLERS-DANLOS SYNDROME, CLASSIC-LIKE, 3; EDSCLL3","url":"https://www.omim.org/entry/620865"},{"mim_id":"620152","title":"HYPOMAGNESEMIA 7, RENAL, WITH OR WITHOUT DILATED CARDIOMYOPATHY; HOMG7","url":"https://www.omim.org/entry/620152"},{"mim_id":"618879","title":"NEURODEVELOPMENTAL DISORDER WITH HYPOTONIA AND CEREBELLAR ATROPHY, WITH OR WITHOUT SEIZURES; NEDHCAS","url":"https://www.omim.org/entry/618879"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"heart muscle","ntpm":51.1}],"url":"https://www.proteinatlas.org/search/F8"},"hgnc":{"alias_symbol":["FVIII","DXS1253E","HEMA"],"prev_symbol":["F8C"]},"alphafold":{"accession":"P00451","domains":[{"cath_id":"2.60.40.420","chopping":"17-39_64-228_250-347","consensus_level":"medium","plddt":88.6512,"start":17,"end":347},{"cath_id":"2.60.40.420","chopping":"401-729","consensus_level":"high","plddt":87.1629,"start":401,"end":729},{"cath_id":"2.60.40.420","chopping":"1715-1734_1748-2034","consensus_level":"high","plddt":87.6309,"start":1715,"end":2034},{"cath_id":"2.60.120.260","chopping":"2041-2193","consensus_level":"medium","plddt":91.013,"start":2041,"end":2193},{"cath_id":"2.60.120.260","chopping":"2194-2351","consensus_level":"medium","plddt":90.4669,"start":2194,"end":2351}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P00451","model_url":"https://alphafold.ebi.ac.uk/files/AF-P00451-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P00451-F1-predicted_aligned_error_v6.png","plddt_mean":60.75},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=F8","jax_strain_url":"https://www.jax.org/strain/search?query=F8"},"sequence":{"accession":"P00451","fasta_url":"https://rest.uniprot.org/uniprotkb/P00451.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P00451/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P00451"}},"corpus_meta":[{"pmid":"2436689","id":"PMC_2436689","title":"FVIII inhibitor IgG subclass and FVIII polypeptide specificity determined by immunoblotting.","date":"1987","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/2436689","citation_count":155,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22103590","id":"PMC_22103590","title":"F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race/ethnicity.","date":"2011","source":"Haemophilia : the official journal of the World Federation of Hemophilia","url":"https://pubmed.ncbi.nlm.nih.gov/22103590","citation_count":110,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12718905","id":"PMC_12718905","title":"Efficient production of human FVIII in hemophilic mice using lentiviral vectors.","date":"2003","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/12718905","citation_count":95,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9973348","id":"PMC_9973348","title":"Conditional stability of the HemA protein (glutamyl-tRNA reductase) regulates heme biosynthesis in Salmonella typhimurium.","date":"1999","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/9973348","citation_count":87,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2544564","id":"PMC_2544564","title":"Cloning, genetic characterization, and nucleotide sequence of the hemA-prfA operon of Salmonella typhimurium.","date":"1989","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/2544564","citation_count":85,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15668336","id":"PMC_15668336","title":"Resin monomer 2-hydroxyethyl methacrylate (HEMA) is a potent inducer of apoptotic cell death in human and mouse cells.","date":"2005","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/15668336","citation_count":83,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24355064","id":"PMC_24355064","title":"HEMA-induced cytotoxicity: oxidative stress, genotoxicity and apoptosis.","date":"2014","source":"International endodontic journal","url":"https://pubmed.ncbi.nlm.nih.gov/24355064","citation_count":69,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2548996","id":"PMC_2548996","title":"Isolation, nucleotide sequence, and preliminary characterization of the Escherichia coli K-12 hemA gene.","date":"1989","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/2548996","citation_count":69,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16223522","id":"PMC_16223522","title":"Pattern of cell death after in vitro exposure to GDMA, TEGDMA, HEMA and two compomer extracts.","date":"2005","source":"Dental materials : official publication of the Academy of Dental Materials","url":"https://pubmed.ncbi.nlm.nih.gov/16223522","citation_count":69,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2110138","id":"PMC_2110138","title":"Cloning and characterization of the hemA region of the Bacillus subtilis chromosome.","date":"1990","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/2110138","citation_count":59,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18634839","id":"PMC_18634839","title":"Gene transfer to hemophilia A mice via oral delivery of FVIII-chitosan nanoparticles.","date":"2008","source":"Journal of controlled release : official journal of the Controlled Release Society","url":"https://pubmed.ncbi.nlm.nih.gov/18634839","citation_count":55,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31843008","id":"PMC_31843008","title":"Curing hemophilia A by NHEJ-mediated ectopic F8 insertion in the mouse.","date":"2019","source":"Genome biology","url":"https://pubmed.ncbi.nlm.nih.gov/31843008","citation_count":55,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25582282","id":"PMC_25582282","title":"Parameters influencing FVIII pharmacokinetics in patients with severe and moderate haemophilia A.","date":"2015","source":"Haemophilia : the official journal of the World Federation of Hemophilia","url":"https://pubmed.ncbi.nlm.nih.gov/25582282","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14693206","id":"PMC_14693206","title":"Antioxidative vitamins decrease cytotoxicity of HEMA and TEGDMA in cultured cell lines.","date":"2004","source":"Archives of oral biology","url":"https://pubmed.ncbi.nlm.nih.gov/14693206","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19183188","id":"PMC_19183188","title":"Recent developments in the understanding of the combined deficiency of FV and FVIII.","date":"2009","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/19183188","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24517184","id":"PMC_24517184","title":"Diagnosis and management challenges in patients with mild haemophilia A and discrepant FVIII measurements.","date":"2014","source":"Haemophilia : the official journal of the World Federation of Hemophilia","url":"https://pubmed.ncbi.nlm.nih.gov/24517184","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8468291","id":"PMC_8468291","title":"5-Aminolevulinic acid availability and control of spectral complex formation in hemA and hemT mutants of Rhodobacter sphaeroides.","date":"1993","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/8468291","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2664455","id":"PMC_2664455","title":"Isolation and nucleotide sequence of the hemA gene of Escherichia coli K12.","date":"1989","source":"Molecular & general genetics : MGG","url":"https://pubmed.ncbi.nlm.nih.gov/2664455","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21795745","id":"PMC_21795745","title":"Mice deficient in LMAN1 exhibit FV and FVIII deficiencies and liver accumulation of α1-antitrypsin.","date":"2011","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/21795745","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16126990","id":"PMC_16126990","title":"Inhibitor development in patients with hemophilia A after continuous infusion of FVIII concentrates.","date":"2005","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/16126990","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19148784","id":"PMC_19148784","title":"Immune response to FVIII in hemophilia A: an overview of risk factors.","date":"2009","source":"Clinical reviews in allergy & immunology","url":"https://pubmed.ncbi.nlm.nih.gov/19148784","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19141160","id":"PMC_19141160","title":"Combined FV and FVIII deficiency.","date":"2008","source":"Haemophilia : the official journal of the World Federation of Hemophilia","url":"https://pubmed.ncbi.nlm.nih.gov/19141160","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28490568","id":"PMC_28490568","title":"Noninvasive detection of F8 int22h-related inversions and sequence variants in maternal plasma of hemophilia carriers.","date":"2017","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/28490568","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17920114","id":"PMC_17920114","title":"HEMA reduces cell proliferation and induces apoptosis in vitro.","date":"2007","source":"Dental materials : official publication of the Academy of Dental Materials","url":"https://pubmed.ncbi.nlm.nih.gov/17920114","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8104869","id":"PMC_8104869","title":"G6PD haplotypes spanning Xq28 from F8C to red/green color vision.","date":"1993","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/8104869","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16470522","id":"PMC_16470522","title":"Regulated release of VWF and FVIII and the biologic implications.","date":"2006","source":"Pediatric blood & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/16470522","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31159172","id":"PMC_31159172","title":"Synthesis and Characterization of Silicone Contact Lenses Based on TRIS-DMA-NVP-HEMA Hydrogels.","date":"2019","source":"Polymers","url":"https://pubmed.ncbi.nlm.nih.gov/31159172","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8837411","id":"PMC_8837411","title":"5-Aminolevulinate production by Escherichia coli containing the Rhodobacter sphaeroides hemA gene.","date":"1996","source":"Applied and environmental microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/8837411","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33545871","id":"PMC_33545871","title":"Electrospun GelMA fibers and p(HEMA) matrix composite for corneal tissue engineering.","date":"2020","source":"Materials science & engineering. C, Materials for biological applications","url":"https://pubmed.ncbi.nlm.nih.gov/33545871","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11857744","id":"PMC_11857744","title":"The identification and classification of 41 novel mutations in the factor VIII gene (F8C).","date":"2002","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/11857744","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"3105317","id":"PMC_3105317","title":"Recombination between the factor VIII gene and the DXS52 locus gives the most probable genetic order as centromere-fra(X)-DXS15-DXS52-F8C-telomere.","date":"1987","source":"American journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/3105317","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31811387","id":"PMC_31811387","title":"Cell Loaded GelMA:HEMA IPN hydrogels for corneal stroma engineering.","date":"2019","source":"Journal of materials science. Materials in medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31811387","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20551083","id":"PMC_20551083","title":"Expression, engineering and characterization of the tumor-targeting heterodimeric immunocytokine F8-IL12.","date":"2010","source":"Protein engineering, design & selection : PEDS","url":"https://pubmed.ncbi.nlm.nih.gov/20551083","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7883699","id":"PMC_7883699","title":"Regulation of the hemA gene during 5-aminolevulinic acid formation in Pseudomonas aeruginosa.","date":"1995","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/7883699","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26025483","id":"PMC_26025483","title":"Assessment of HEMA and TEGDMA induced DNA damage by multiple genotoxicological endpoints in human lymphocytes.","date":"2015","source":"Dental materials : official publication of the Academy of Dental Materials","url":"https://pubmed.ncbi.nlm.nih.gov/26025483","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27471234","id":"PMC_27471234","title":"T cells from hemophilia A subjects recognize the same HLA-restricted FVIII epitope with a narrow TCR repertoire.","date":"2016","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/27471234","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26921444","id":"PMC_26921444","title":"Targeting of the human F8 at the multicopy rDNA locus in Hemophilia A patient-derived iPSCs using TALENickases.","date":"2016","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/26921444","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33275657","id":"PMC_33275657","title":"Partial F8 gene duplication (factor VIII Padua) associated with high factor VIII levels and familial thrombophilia.","date":"2021","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/33275657","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18800199","id":"PMC_18800199","title":"Expression of a hemA gene from Agrobacterium radiobacter in a rare codon optimizing Escherichia coli for improving 5-aminolevulinate production.","date":"2008","source":"Applied biochemistry and biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/18800199","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12073043","id":"PMC_12073043","title":"The Pseudomonas aeruginosa hemA promoter is regulated by Anr, Dnr, NarL and Integration Host Factor.","date":"2002","source":"Molecular genetics and genomics : MGG","url":"https://pubmed.ncbi.nlm.nih.gov/12073043","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37874897","id":"PMC_37874897","title":"Thermoresponsive Smart Copolymer Coatings Based on P(NIPAM-co-HEMA) and P(OEGMA-co-HEMA) Brushes for Regenerative Medicine.","date":"2023","source":"ACS biomaterials science & engineering","url":"https://pubmed.ncbi.nlm.nih.gov/37874897","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23042590","id":"PMC_23042590","title":"Mesenchymal stem cells contribute to endogenous FVIII:c production.","date":"2013","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/23042590","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23477355","id":"PMC_23477355","title":"Stem cell suspension injected HEMA-lactate-dextran cryogels for regeneration of critical sized bone defects.","date":"2013","source":"Artificial cells, nanomedicine, and biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/23477355","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31785023","id":"PMC_31785023","title":"Clinical manifestation of hemophilia A in the absence of mutations in the F8 gene that encodes FVIII: role of microRNAs.","date":"2019","source":"Transfusion","url":"https://pubmed.ncbi.nlm.nih.gov/31785023","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29444872","id":"PMC_29444872","title":"FVIII proteins with a modified immunodominant T-cell epitope exhibit reduced immunogenicity and normal FVIII activity.","date":"2018","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/29444872","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25611311","id":"PMC_25611311","title":"Phenotype-genotype correlations in hemophilia A carriers are consistent with the binary role of the phase between F8 and X-chromosome inactivation.","date":"2015","source":"Journal of thrombosis and haemostasis : JTH","url":"https://pubmed.ncbi.nlm.nih.gov/25611311","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23551875","id":"PMC_23551875","title":"Characterization of large deletions in the F8 gene using multiple competitive amplification and the genome walking technique.","date":"2013","source":"Journal of thrombosis and haemostasis : JTH","url":"https://pubmed.ncbi.nlm.nih.gov/23551875","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24729686","id":"PMC_24729686","title":"Fc-fusion technology and recombinant FVIII and FIX in the management of the hemophilias.","date":"2014","source":"Drug design, development and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/24729686","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32670285","id":"PMC_32670285","title":"B Cell Depletion Eliminates FVIII Memory B Cells and Enhances AAV8-coF8 Immune Tolerance Induction When Combined With Rapamycin.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32670285","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32351497","id":"PMC_32351497","title":"The Immune Response to the fVIII Gene Therapy in Preclinical Models.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32351497","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8169226","id":"PMC_8169226","title":"5-Aminolevulinic acid synthesis in Escherichia coli requires expression of hemA.","date":"1994","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/8169226","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31461952","id":"PMC_31461952","title":"Solvent and HEMA Increase Adhesive Toxicity and Cytokine Release from Dental Pulp Cells.","date":"2019","source":"Materials (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/31461952","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25968591","id":"PMC_25968591","title":"Cell toxicity of 2-hydroxyethyl methacrylate (HEMA): the role of oxidative stress.","date":"2015","source":"European journal of oral sciences","url":"https://pubmed.ncbi.nlm.nih.gov/25968591","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15574962","id":"PMC_15574962","title":"Effects of expression of hemA and hemB genes on production of porphyrin in Propionibacterium freudenreichii.","date":"2004","source":"Applied and environmental microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/15574962","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16215169","id":"PMC_16215169","title":"Mg-protoporphyrin IX and heme control HEMA, the gene encoding the first specific step of tetrapyrrole biosynthesis, in Chlamydomonas reinhardtii.","date":"2005","source":"Eukaryotic cell","url":"https://pubmed.ncbi.nlm.nih.gov/16215169","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37285902","id":"PMC_37285902","title":"Comprehensive Analysis of Hemophilia A (CAHEA): Towards Full Characterization of the F8 Gene Variants by Long-Read Sequencing.","date":"2023","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/37285902","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26315604","id":"PMC_26315604","title":"The role of previously untreated patient studies in understanding the development of FVIII inhibitors.","date":"2015","source":"Haemophilia : the official journal of the World Federation of Hemophilia","url":"https://pubmed.ncbi.nlm.nih.gov/26315604","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20626616","id":"PMC_20626616","title":"WAG-F8(m1Ycb) rats harboring a factor VIII gene mutation provide a new animal model for hemophilia A.","date":"2010","source":"Journal of thrombosis and haemostasis : JTH","url":"https://pubmed.ncbi.nlm.nih.gov/20626616","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22847994","id":"PMC_22847994","title":"Human gingival fibroblasts stress response to HEMA: A role for protein kinase C α.","date":"2012","source":"Journal of biomedical materials research. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/22847994","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2034217","id":"PMC_2034217","title":"Cloning and nucleotide sequence of the hemA gene of Agrobacterium radiobacter.","date":"1991","source":"Molecular & general genetics : MGG","url":"https://pubmed.ncbi.nlm.nih.gov/2034217","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36107620","id":"PMC_36107620","title":"Immune tolerance against infused FVIII in hemophilia A is mediated by PD-L1+ Tregs.","date":"2022","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/36107620","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23387800","id":"PMC_23387800","title":"Cytokine profile and FVIII inhibitors development in haemophilia A.","date":"2013","source":"Haemophilia : the official journal of the World Federation of Hemophilia","url":"https://pubmed.ncbi.nlm.nih.gov/23387800","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15780006","id":"PMC_15780006","title":"Characterization of a spontaneously polarizing HT-29 cell line, HT-29/cl.f8.","date":"2004","source":"In vitro cellular & developmental biology. Animal","url":"https://pubmed.ncbi.nlm.nih.gov/15780006","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24118514","id":"PMC_24118514","title":"In silico calculated affinity of FVIII-derived peptides for HLA class II alleles predicts inhibitor development in haemophilia A patients with missense mutations in the F8 gene.","date":"2013","source":"Haemophilia : the official journal of the World Federation of Hemophilia","url":"https://pubmed.ncbi.nlm.nih.gov/24118514","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38452208","id":"PMC_38452208","title":"Vector integration and fate in the hemophilia dog liver multiple years after AAV-FVIII gene transfer.","date":"2024","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/38452208","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33552050","id":"PMC_33552050","title":"Immune Responses to Plasma-Derived Versus Recombinant FVIII Products.","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33552050","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18549909","id":"PMC_18549909","title":"The role of VWF in the immunogenicity of FVIII.","date":"2008","source":"Thrombosis research","url":"https://pubmed.ncbi.nlm.nih.gov/18549909","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26566286","id":"PMC_26566286","title":"Engineering less immunogenic and antigenic FVIII proteins.","date":"2015","source":"Cellular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/26566286","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37995690","id":"PMC_37995690","title":"Structural insights into the assembly and mechanism of mpox virus DNA polymerase complex F8-A22-E4-H5.","date":"2023","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/37995690","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12204009","id":"PMC_12204009","title":"Prevalence of small rearrangements in the factor VIII gene F8C among patients with severe hemophilia A.","date":"2002","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/12204009","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30609275","id":"PMC_30609275","title":"The impact of GPIbα on platelet-targeted FVIII gene therapy in hemophilia A mice with pre-existing anti-FVIII immunity.","date":"2019","source":"Journal of thrombosis and haemostasis : JTH","url":"https://pubmed.ncbi.nlm.nih.gov/30609275","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17610559","id":"PMC_17610559","title":"Mutations in the MCFD2 gene are predominant among patients with hereditary combined FV and FVIII deficiency (F5F8D) in India.","date":"2007","source":"Haemophilia : the official journal of the World Federation of Hemophilia","url":"https://pubmed.ncbi.nlm.nih.gov/17610559","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25589203","id":"PMC_25589203","title":"Experimental self-etching HEMA-free adhesive systems: cytotoxicity and degree of conversion.","date":"2015","source":"Journal of materials science. Materials in medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25589203","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2842318","id":"PMC_2842318","title":"Cloning of the Rhodobacter capsulatus hemA gene.","date":"1988","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/2842318","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26915717","id":"PMC_26915717","title":"Characterization of five associations of F8 missense mutations containing FVIII B domain mutations.","date":"2016","source":"Haemophilia : the official journal of the World Federation of Hemophilia","url":"https://pubmed.ncbi.nlm.nih.gov/26915717","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26435345","id":"PMC_26435345","title":"T cell response to FVIII.","date":"2015","source":"Cellular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/26435345","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35491676","id":"PMC_35491676","title":"Liver gene therapy with intein-mediated F8 trans-splicing corrects mouse haemophilia A.","date":"2022","source":"EMBO molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35491676","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31638432","id":"PMC_31638432","title":"Two metabolites isolated from endophytic fungus Coniochaeta sp. F-8 in Ageratina adenophora exhibit antioxidative activity and cytotoxicity.","date":"2019","source":"Natural product research","url":"https://pubmed.ncbi.nlm.nih.gov/31638432","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32258210","id":"PMC_32258210","title":"Defining the Optimal FVIII Transgene for Placental Cell-Based Gene Therapy to Treat Hemophilia A.","date":"2020","source":"Molecular therapy. Methods & clinical development","url":"https://pubmed.ncbi.nlm.nih.gov/32258210","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36696179","id":"PMC_36696179","title":"Race, ethnicity, F8 variants, and inhibitor risk: analysis of the \"My Life Our Future\" hemophilia A database.","date":"2022","source":"Journal of thrombosis and haemostasis : JTH","url":"https://pubmed.ncbi.nlm.nih.gov/36696179","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26383047","id":"PMC_26383047","title":"Complexity and diversity of F8 genetic variations in the 1000 genomes.","date":"2015","source":"Journal of thrombosis and haemostasis : JTH","url":"https://pubmed.ncbi.nlm.nih.gov/26383047","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31089407","id":"PMC_31089407","title":"Protection against HEMA-Induced Mitochondrial Injury In Vitro by Nrf2 Activation.","date":"2019","source":"Oxidative medicine and cellular longevity","url":"https://pubmed.ncbi.nlm.nih.gov/31089407","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28448958","id":"PMC_28448958","title":"Evaluation of F8-TNF-α in Models of Early and Progressive Metastatic Osteosarcoma.","date":"2017","source":"Translational oncology","url":"https://pubmed.ncbi.nlm.nih.gov/28448958","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28188892","id":"PMC_28188892","title":"The dental monomer hydroxyethyl methacrylate (HEMA) counteracts lipopolysaccharide-induced IL-1β release-Possible role of glutathione.","date":"2017","source":"Toxicology letters","url":"https://pubmed.ncbi.nlm.nih.gov/28188892","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10831786","id":"PMC_10831786","title":"Changes in cell phospholipid metabolism in vitro in the presence of HEMA and its degradation products.","date":"2000","source":"Dental materials : official publication of the Academy of Dental Materials","url":"https://pubmed.ncbi.nlm.nih.gov/10831786","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18597256","id":"PMC_18597256","title":"The permeability of EUDRAGIT RL and HEMA-MMA microcapsules to glucose and inulin.","date":"1990","source":"Biotechnology and bioengineering","url":"https://pubmed.ncbi.nlm.nih.gov/18597256","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18665854","id":"PMC_18665854","title":"Severe haemophilia A in a female resulting from an inherited gross deletion and a de novo codon deletion in the F8 gene.","date":"2008","source":"Haemophilia : the official journal of the World Federation of Hemophilia","url":"https://pubmed.ncbi.nlm.nih.gov/18665854","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12203998","id":"PMC_12203998","title":"Identification of seven novel mutations of F8C by DHPLC.","date":"2002","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/12203998","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26689265","id":"PMC_26689265","title":"Multidimensional Genome-wide Analyses Show Accurate FVIII Integration by ZFN in Primary Human Cells.","date":"2015","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/26689265","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32850803","id":"PMC_32850803","title":"Further Evidence That MicroRNAs Can Play a Role in Hemophilia A Disease Manifestation: F8 Gene Downregulation by miR-19b-3p and miR-186-5p.","date":"2020","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/32850803","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27214537","id":"PMC_27214537","title":"Polymorphisms associated with the FVIII and FIX genes in the Turkish population.","date":"1995","source":"Haemophilia : the official journal of the World Federation of Hemophilia","url":"https://pubmed.ncbi.nlm.nih.gov/27214537","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36998673","id":"PMC_36998673","title":"Current Understanding of Inherited Modifiers of FVIII Pharmacokinetic Variation.","date":"2023","source":"Pharmacogenomics and personalized medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36998673","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36490287","id":"PMC_36490287","title":"Separate roles of LMAN1 and MCFD2 in ER-to-Golgi trafficking of FV and FVIII.","date":"2023","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/36490287","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14699993","id":"PMC_14699993","title":"Long distance PCR in detection of inversion mutations of F8C gene in hemophilia A patients.","date":"2003","source":"General physiology and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/14699993","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34662354","id":"PMC_34662354","title":"Role of ADAMTS13, VWF and F8 genes in deep vein thrombosis.","date":"2021","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/34662354","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25503412","id":"PMC_25503412","title":"Characterisation and quantification of F8 transcripts of ten putative splice site mutations.","date":"2014","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/25503412","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18434078","id":"PMC_18434078","title":"Expression of procollagen alpha1 type I and tenascin proteins induced by HEMA in human pulp fibroblasts.","date":"2008","source":"Toxicology in vitro : an international journal published in association with BIBRA","url":"https://pubmed.ncbi.nlm.nih.gov/18434078","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33644070","id":"PMC_33644070","title":"Restoration of FVIII Function and Phenotypic Rescue in Hemophilia A Mice by Transplantation of MSCs Derived From F8-Modified iPSCs.","date":"2021","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/33644070","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27887776","id":"PMC_27887776","title":"Critical role of superoxide anions and hydroxyl radicals in HEMA-induced apoptosis.","date":"2016","source":"Dental materials : official publication of the Academy of Dental Materials","url":"https://pubmed.ncbi.nlm.nih.gov/27887776","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27292088","id":"PMC_27292088","title":"Identification of mutations in the F8 and F9 gene in families with haemophilia using targeted high-throughput sequencing.","date":"2016","source":"Haemophilia : the official journal of the World Federation of Hemophilia","url":"https://pubmed.ncbi.nlm.nih.gov/27292088","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"6438528","id":"PMC_6438528","title":"Molecular cloning of a cDNA encoding human antihaemophilic factor.","date":"1984","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/6438528","citation_count":834,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22808956","id":"PMC_22808956","title":"Genetically distinct subsets within ANCA-associated vasculitis.","date":"2012","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22808956","citation_count":726,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8275087","id":"PMC_8275087","title":"Inversions disrupting the factor VIII gene are a common cause of severe haemophilia A.","date":"1993","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/8275087","citation_count":689,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14718574","id":"PMC_14718574","title":"The human plasma proteome: a nonredundant list developed by combination of four separate sources.","date":"2004","source":"Molecular & cellular proteomics : MCP","url":"https://pubmed.ncbi.nlm.nih.gov/14718574","citation_count":658,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"6438526","id":"PMC_6438526","title":"Expression of active human factor VIII from recombinant DNA clones.","date":"1984","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/6438526","citation_count":620,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12524220","id":"PMC_12524220","title":"The dynamics of thrombin formation.","date":"2003","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/12524220","citation_count":387,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16335952","id":"PMC_16335952","title":"Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry.","date":"2005","source":"Journal of proteome research","url":"https://pubmed.ncbi.nlm.nih.gov/16335952","citation_count":350,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9834200","id":"PMC_9834200","title":"The life cycle of coagulation factor VIII in view of its structure and function.","date":"1998","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/9834200","citation_count":333,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20231535","id":"PMC_20231535","title":"Novel associations of multiple genetic loci with plasma levels of factor VII, factor VIII, and von Willebrand factor: The CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) Consortium.","date":"2010","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/20231535","citation_count":295,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22282501","id":"PMC_22282501","title":"F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis.","date":"2012","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/22282501","citation_count":287,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12717434","id":"PMC_12717434","title":"Bleeding due to disruption of a cargo-specific ER-to-Golgi transport complex.","date":"2003","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12717434","citation_count":234,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"1898735","id":"PMC_1898735","title":"Sulfation of Tyr1680 of human blood coagulation factor VIII is essential for the interaction of factor VIII with von Willebrand factor.","date":"1991","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/1898735","citation_count":220,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16380445","id":"PMC_16380445","title":"Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A.","date":"2005","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/16380445","citation_count":212,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21988832","id":"PMC_21988832","title":"Toward an understanding of the protein interaction network of the human liver.","date":"2011","source":"Molecular systems biology","url":"https://pubmed.ncbi.nlm.nih.gov/21988832","citation_count":207,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2987704","id":"PMC_2987704","title":"Detection and sequence of mutations in the factor VIII gene of haemophiliacs.","date":"1985","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/2987704","citation_count":203,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"3134349","id":"PMC_3134349","title":"Association of the factor VIII light chain with von Willebrand factor.","date":"1988","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/3134349","citation_count":202,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18400180","id":"PMC_18400180","title":"Crystal structure of human factor VIII: implications for the formation of the factor IXa-factor VIIIa complex.","date":"2008","source":"Structure (London, England : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/18400180","citation_count":185,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23926300","id":"PMC_23926300","title":"Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A.","date":"2013","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/23926300","citation_count":181,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"27587878","id":"PMC_27587878","title":"Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A.","date":"2016","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/27587878","citation_count":180,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12615788","id":"PMC_12615788","title":"No evidence of association between prothrombotic gene polymorphisms and the development of acute myocardial infarction at a young age.","date":"2003","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/12615788","citation_count":177,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9569189","id":"PMC_9569189","title":"Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK Haemophilia Centre Directors Organisation.","date":"1998","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/9569189","citation_count":174,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"1939075","id":"PMC_1939075","title":"Activated protein C-catalyzed inactivation of human factor VIII and factor VIIIa. Identification of cleavage sites and correlation of proteolysis with cofactor activity.","date":"1991","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/1939075","citation_count":169,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14684146","id":"PMC_14684146","title":"Activation of factor VIII and mechanisms of cofactor action.","date":"2004","source":"Blood reviews","url":"https://pubmed.ncbi.nlm.nih.gov/14684146","citation_count":165,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19913121","id":"PMC_19913121","title":"Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip.","date":"2009","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19913121","citation_count":164,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9218428","id":"PMC_9218428","title":"The acidic region of the factor VIII light chain and the C2 domain together form the high affinity binding site for von willebrand factor.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9218428","citation_count":159,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23243272","id":"PMC_23243272","title":"Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients.","date":"2012","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/23243272","citation_count":158,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21041718","id":"PMC_21041718","title":"Codon optimization of human factor VIII cDNAs leads to high-level expression.","date":"2010","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/21041718","citation_count":157,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"1908096","id":"PMC_1908096","title":"Molecular characterization of severe hemophilia A suggests that about half the mutations are not within the coding regions and splice junctions of the factor VIII gene.","date":"1991","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/1908096","citation_count":153,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":49494,"output_tokens":3924,"usd":0.103671},"stage2":{"model":"claude-opus-4-6","input_tokens":7361,"output_tokens":3310,"usd":0.179333},"total_usd":0.625576,"stage1_batch_id":"msgbatch_0118RScg3WGaGkaZRtWZbtce","stage2_batch_id":"msgbatch_01Cpfzvtbj42aqp5oYZ5Te2s","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":63272,"output_tokens":6123,"usd":0.14083},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":9689,"output_tokens":3442,"usd":0.201742}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2009,\n      \"finding\": \"The LMAN1-MCFD2 complex functions as a cargo receptor for ER-to-Golgi transport of FVIII (and FV). MCFD2 is an EF-hand domain protein that forms a calcium-dependent heteromeric complex with LMAN1; missense mutations in the EF-hand domains of MCFD2 abolish interaction with LMAN1. The B domain of FVIII may mediate its interaction with the LMAN1-MCFD2 complex.\",\n      \"method\": \"Genetic analysis of F5F8D patients, characterization of LMAN1/MCFD2 mutations, biochemical interaction studies\",\n      \"journal\": \"British journal of haematology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — replicated across multiple labs, supported by patient genetics and biochemical interaction data\",\n      \"pmids\": [\"19183188\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"LMAN1-deficient mice show ~50% reduction in plasma FV and FVIII and platelet FV, confirming the LMAN1-MCFD2 complex as a cargo receptor for ER-to-Golgi transport of FVIII. LMAN1 deficiency causes ER distension with accumulation of α1-antitrypsin and GRP78 in hepatocytes.\",\n      \"method\": \"Lman1 knockout mouse model, plasma factor activity assays, in vitro COPII vesicle formation assay, electron microscopy, immunostaining\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with defined cellular/molecular phenotype, multiple orthogonal methods\",\n      \"pmids\": [\"21795745\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Overexpression of wild-type or mutant MCFD2 rescues FV/FVIII secretion in LMAN1-deficient cells, indicating that cargo binding and transport are carried out by MCFD2 while LMAN1 primarily serves as a shuttling carrier for MCFD2. LMAN1 carbohydrate-binding is not essential for FV/FVIII transport.\",\n      \"method\": \"LMAN1/MCFD2-deficient cell lines (HEK293T, HepG2, HCT116), overexpression rescue assays, FVIII/FV secretion assays\",\n      \"journal\": \"Blood advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple cell lines, gain- and loss-of-function experiments with direct functional readout\",\n      \"pmids\": [\"36490287\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Regulated (stimulated) secretion of FVIII occurs only when FVIII is synthesized together with VWF in endothelial cells, indicating that endogenous co-synthesis with VWF is required to establish a regulated storage pool of FVIII.\",\n      \"method\": \"Regulated secretion assay in endothelial cells with DDAVP stimulation; co-expression studies\",\n      \"journal\": \"Pediatric blood & cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct functional secretion assay, single lab\",\n      \"pmids\": [\"16470522\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1987,\n      \"finding\": \"FVIII inhibitor epitopes localize to the 92-kDa polypeptide (and its 54-kDa/44-kDa thrombin fragments) and/or the 80-kDa polypeptide (and its 72-kDa thrombin fragment); inhibitors are of restricted polyclonal IgG origin (predominantly IgG-1 and IgG-4), and different IgG subclasses within an inhibitor plasma can differ in their FVIII polypeptide reactivity.\",\n      \"method\": \"Immunoblotting of purified FVIII with inhibitor plasmas, monoclonal anti-IgG subclass antibodies, affinity purification and radial immunodiffusion\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct immunoblot epitope mapping with 76 inhibitor plasmas, multiple orthogonal methods, highly cited\",\n      \"pmids\": [\"2436689\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CD4+ T cells from hemophilia A subjects with inhibitors recognize an immunodominant HLA-DRA*01-DRB1*01:01-restricted epitope within FVIII peptide 2194–2213, with a narrow TCR β-chain repertoire; high-avidity T-cell clones predominantly express a single TCRB gene.\",\n      \"method\": \"MHC class II tetramers, T-cell clone isolation and proliferation assays, TCR β-chain sequencing, high-throughput immunosequencing\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (tetramers, cloning, high-throughput sequencing), confirmed across multiple subjects\",\n      \"pmids\": [\"27471234\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Amino acid substitutions at FVIII residues F2196 and M2199 within the immunodominant DRB1*01:01-restricted epitope (FVIII2194-2213) abrogate T-cell proliferation while retaining procoagulant activity; F2196K substitution eliminates DRB1*01:01-restricted immunogenicity with expression and activity comparable to wild-type BDD-FVIII.\",\n      \"method\": \"Peptide-MHCII binding assays, T-cell proliferation assays, recombinant BDD-FVIII protein expression and activity assays, epitope prediction algorithms\",\n      \"journal\": \"Blood advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro mutagenesis with functional validation of both immunogenicity and coagulant activity\",\n      \"pmids\": [\"29444872\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Human mesenchymal stem cells (MSC) from lung, liver, brain, and bone marrow express FVIII mRNA and secrete functional FVIII protein (detected by aPTT and chromogenic assays). In MSC, FVIII localizes to the perinuclear region rather than in Weibel-Palade body-like granules.\",\n      \"method\": \"qRT-PCR, confocal microscopy with anti-FVIII antibody, aPTT and chromogenic activity assays on supernatants and lysates\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple cell types and orthogonal methods, single lab\",\n      \"pmids\": [\"23042590\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"In WAG/RijYcb rats, a point mutation Leu176Pro in the A1 domain of the FVIII protein (encoded by F8 on chromosome 18, autosomal in rats) causes FVIII deficiency; the mutation is predicted to disrupt tertiary structure of the FVIII molecule, and the coagulation defect is corrected by human recombinant FVIII.\",\n      \"method\": \"F8 cDNA sequencing, clotting factor activity assays, phenotypic correction with recombinant FVIII\",\n      \"journal\": \"Journal of thrombosis and haemostasis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct mutation identification with functional rescue, single lab\",\n      \"pmids\": [\"20626616\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"miRNAs miR-374b-5p and miR-30c-5p target the 3′UTR of F8 mRNA; overexpression of these miRNAs decreases FVIII expression in cell lines constitutively expressing FVIII, and an miR-30c inhibitor partially restores FVIII expression.\",\n      \"method\": \"miRNA sequencing, overexpression and inhibitor transfection in FVIII-expressing cell lines, FVIII activity assays\",\n      \"journal\": \"Transfusion\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — functional gain/loss assays with direct FVIII readout, single lab, two miRNAs tested\",\n      \"pmids\": [\"31785023\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"miRNAs miR-19b-3p and miR-186-5p directly interact with F8 mRNA (identified by RNA-affinity purification) and suppress F8/FVIII expression by targeting the 3′UTR in mammalian cells.\",\n      \"method\": \"In vivo RNA-affinity purification, overexpression in mammalian cells, FVIII activity/expression assays\",\n      \"journal\": \"Frontiers in cell and developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — orthogonal identification (affinity purification) plus functional overexpression assay\",\n      \"pmids\": [\"32850803\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"A 23.4-kb tandem duplication of F8 (promoter, exon 1, and part of intron 1) causes twofold or greater upregulation of F8 mRNA; a 927-bp region within F8 intron 1 shows >45-fold increased luciferase reporter activity in endothelial cells, identifying an intronic enhancer element driving elevated FVIII expression.\",\n      \"method\": \"Genetic analysis, qRT-PCR, chromatin accessibility (open chromatin signatures), luciferase reporter assay in endothelial cells\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — reporter assay with defined sequence element, supported by mRNA quantification and chromatin data\",\n      \"pmids\": [\"33275657\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Immune tolerance to FVIII is maintained by PD-L1-expressing regulatory T cells (Tregs) that ligate PD-1 on FVIII-specific B cells, inducing their apoptosis; FVIII-deficient mice lack such Tregs and develop inhibitors; repetitive FVIII injection (ITI) induces FVIII-specific PD-L1+ Tregs and re-engages removal of inhibitor-forming B cells.\",\n      \"method\": \"Mouse FVIII-deficient model, ITI mouse model, flow cytometry for PD-L1/PD-1, Treg depletion/transfer, apoptosis assays, human sample analysis post-ITI\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic pathway established in mouse model with multiple orthogonal methods and human validation\",\n      \"pmids\": [\"36107620\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"VWF inhibits uptake of FVIII by immature dendritic cells and reduces activation of FVIII-specific T cells in a dose-dependent manner; recombinant VWF lacking the FVIII-binding domain does not inhibit T-cell activation, indicating VWF reduces FVIII immunogenicity through direct FVIII binding that blocks antigen uptake.\",\n      \"method\": \"In vitro dendritic cell FVIII uptake assay, T-cell activation assay, recombinant VWF domain deletion constructs\",\n      \"journal\": \"Thrombosis research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro mechanistic assays with domain-deletion controls, single lab review compilation\",\n      \"pmids\": [\"18549909\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"F8 splice-site mutations produce multiple aberrant transcripts (exon skipping, cryptic splice-site activation, partial normal splicing); quantitative RT-PCR shows that residual wild-type F8 transcript levels correlate with coagulation phenotype severity.\",\n      \"method\": \"RT-PCR, quantitative real-time RT-PCR, co-amplification fluorescent PCR, mRNA analysis from patient samples\",\n      \"journal\": \"Thrombosis and haemostasis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct mRNA analysis with quantification across 10 mutations, functional correlation with phenotype\",\n      \"pmids\": [\"25503412\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"FVIII B-domain missense variants (p.D963N, p.S806T, p.G873D, p.H998Q, p.Q1225R) show normal FVIII activity and antigen when expressed in COS-1 cells, while missense variants outside the B domain (p.V682L, p.S714L, p.V592D, p.C573F) cause significantly reduced FVIII activity, establishing that the B domain variants are non-pathogenic polymorphisms.\",\n      \"method\": \"Transient expression in COS-1 cells, FVIII activity and antigen assays, thermostability analysis\",\n      \"journal\": \"Haemophilia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — in vitro expression and functional assay with mutagenesis, single lab\",\n      \"pmids\": [\"26915717\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"FVIII (F8) is a procofactor that undergoes ER-to-Golgi trafficking via the LMAN1-MCFD2 cargo receptor complex (with MCFD2 performing direct cargo binding and LMAN1 serving as a membrane shuttle), is stabilized in plasma by VWF (which also shields it from antigen-presenting cells to reduce immunogenicity), contains functionally distinct A1, A2, A3, C1, and C2 domains with a dispensable B domain, harbors intronic enhancer elements (notably in intron 1) that regulate transcription in endothelial cells, and its expression is fine-tuned post-transcriptionally by miRNAs targeting the F8 3′UTR; immune tolerance to infused FVIII is maintained through PD-L1+ Treg-mediated apoptosis of FVIII-specific B cells, and immunodominant T-cell responses to therapeutic FVIII map to a narrow set of HLA-restricted epitopes in the C2 domain.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\nI'll classify each paper first, then extract discoveries only from KEEP papers.\n\n**Classification:**\n- Papers about coagulation F8/FVIII (human gene): KEEP\n- Papers about bacterial hemA (glutamyl-tRNA reductase / ALA synthase): EXCLUDE (symbol collision - different gene)\n- Papers about dental monomer HEMA (2-hydroxyethyl methacrylate): EXCLUDE (different compound entirely)\n- Papers about mpox virus F8 DNA polymerase: EXCLUDE (symbol collision - viral gene)\n- Papers about F8-IL12/F8-TNF antibody fragments targeting fibronectin EDA: EXCLUDE (antibody fragment, not the F8 coagulation gene)\n- Papers about HT-29/cl.f8 cell line: EXCLUDE (different entity)\n- Papers about fungal endophyte Coniochaeta sp. F-8: EXCLUDE (symbol collision)\n- GWAS/eQTL/expression only: EXCLUDE per rules\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1984,\n      \"finding\": \"The complete mRNA sequence encoding human coagulation factor VIII was cloned and expressed in mammalian cells, revealing a single-chain precursor of 2,351 amino acids (Mr ~267 kDa) with a domain structure showing sequence repeats and structural relatedness to factor V and ceruloplasmin; recombinant protein corrected clotting time in hemophiliac plasma.\",\n      \"method\": \"cDNA cloning, sequencing, and expression in cultured mammalian cells; functional clotting assay\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — original molecular cloning with functional validation, foundational study replicated by two independent groups simultaneously\",\n      \"pmids\": [\"6438528\", \"6438526\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1985,\n      \"finding\": \"Point mutations (nonsense) and partial deletions in the F8 gene were identified as molecular causes of hemophilia A, establishing the heterogeneous mutational basis of the disease.\",\n      \"method\": \"Southern blotting and direct sequencing of F8 gene in 92 hemophilia A patients\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct sequencing with functional correlation; foundational study, widely replicated\",\n      \"pmids\": [\"2987704\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1988,\n      \"finding\": \"The FVIII light chain (80 kDa), but not the heavy chain, binds to von Willebrand factor (vWF) with a stoichiometry of one light chain per vWF subunit; thrombin cleavage removing an acidic 41-residue N-terminal peptide from the light chain completely abolishes vWF binding, and intact FVIII bound to vWF is fully released after thrombin proteolysis.\",\n      \"method\": \"Analytical velocity sedimentation of purified porcine FVIII chains with multimeric vWF; thrombin proteolysis experiments\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with purified components, quantitative binding stoichiometry established\",\n      \"pmids\": [\"3134349\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"Sulfation of Tyr1680 in the acidic region of the FVIII light chain is essential for interaction with vWF; site-directed mutagenesis replacing Tyr1680 with Phe completely abolished vWF binding, and expression in the presence of chlorate (sulfation inhibitor) also abrogated binding.\",\n      \"method\": \"Site-directed mutagenesis, expression in COS-1 cells, vWF binding assay, cell-free sulfation studies with tyrosylprotein sulfotransferase\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis combined with biochemical binding assay and enzymatic sulfation study; multiple orthogonal methods in single study\",\n      \"pmids\": [\"1898735\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"Activated protein C (APC) inactivates factor VIII and factor VIIIa by proteolytic cleavage within the heavy chain at Arg336 and Arg562 (and proposed Arg740); cleavage at Arg562 most closely correlates with loss of cofactor activity and promotes dissociation of the A2 domain from the A1/light chain dimer.\",\n      \"method\": \"In vitro proteolysis of purified human FVIII/FVIIIa with APC, NH2-terminal sequencing of cleavage fragments, anti-A2 monoclonal antibody reactivity, gel filtration analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with purified components, direct N-terminal sequencing of cleavage sites, multiple orthogonal methods\",\n      \"pmids\": [\"1939075\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"Inversions disrupting the factor VIII gene, resulting from intrachromosomal recombination between a homologous sequence in intron 22 (int22h) and upstream copies of that sequence, account for approximately 45% of severe hemophilia A cases.\",\n      \"method\": \"Southern blot assay detecting inversion-specific restriction fragment patterns in hemophilia A patient cohorts\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct molecular detection in large patient cohort; independently replicated as the most common severe HA mutation\",\n      \"pmids\": [\"8275087\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Both the acidic region (residues 1649–1689, including sulfated Tyr1680) and the C2 domain of the FVIII light chain are directly involved in forming the high-affinity vWF-binding site; the acidic region is also required to maintain the optimal conformation of the vWF-binding site within C2.\",\n      \"method\": \"Limited V8 protease digestion of FVIII light chain to generate defined fragments; surface plasmon resonance binding measurements; anti-C2 and anti-acidic region monoclonal antibody assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — quantitative binding kinetics with purified fragments by SPR, multiple truncation mutants tested\",\n      \"pmids\": [\"9218428\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"FVIII circulates as a metal ion-dependent heterodimer of heavy chain and light chain; activation by thrombin or factor Xa involves limited proteolysis at three sites yielding factor VIIIa, which dramatically increases the catalytic efficiency of factor IXa in activating factor X primarily by increasing kcat.\",\n      \"method\": \"Biochemical characterization review synthesizing in vitro proteolysis, activity assays, and structural data\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — synthesis of multiple reconstitution studies; established mechanistic framework\",\n      \"pmids\": [\"9834200\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Mutations in MCFD2, an EF-hand domain protein that forms a calcium-dependent heteromeric complex with LMAN1 in the ERGIC, cause combined FV and FVIII deficiency (F5F8D), establishing that the LMAN1-MCFD2 complex functions as a cargo receptor for ER-to-Golgi transport of both FV and FVIII.\",\n      \"method\": \"Patient mutation analysis, subcellular co-localization, co-immunoprecipitation demonstrating calcium-dependent MCFD2-LMAN1 interaction, yeast two-hybrid\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal co-IP, patient genetics, and functional secretion assays; independently replicated\",\n      \"pmids\": [\"12717434\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Factor VIIIa acts as a cofactor by markedly increasing the catalytic rate constant (kcat) of factor IXa for factor X activation; thrombin or factor Xa activate FVIII by cleaving at three defined sites in the heavy chain (Arg372, Arg740) and light chain (Arg1689), altering covalent structure and conformation.\",\n      \"method\": \"In vitro proteolysis with thrombin/FXa, kinetic assays of FIXa/FVIIIa complex activity, fragment characterization\",\n      \"journal\": \"Blood reviews\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mechanistic review synthesizing multiple in vitro reconstitution studies with defined cleavage site mapping\",\n      \"pmids\": [\"14684146\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"X-ray crystal structure of B domain-deleted human factor VIII revealed five globular domains with one Ca2+ and two Cu2+ ions; A1 and A3 domains form the base of a triangular A-domain heterotrimer; C1 and C2 domains contain membrane-binding features; in silico docking with factor IXa suggested an extended interface spanning both heavy and light chains of FVIII.\",\n      \"method\": \"X-ray crystallography (crystal structure determination) of BDD-FVIII; in silico docking modeling with factor IXa based on biochemical constraints\",\n      \"journal\": \"Structure\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure with functional modeling; single rigorous structural study\",\n      \"pmids\": [\"18400180\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"The LMAN1-MCFD2 complex serves as a cargo receptor for ER-to-Golgi transport of FV and FVIII; MCFD2 missense mutations in EF-hand domains abolish the calcium-dependent interaction with LMAN1; the B domain of FVIII may be important in mediating its interaction with the LMAN1-MCFD2 complex.\",\n      \"method\": \"Patient mutation analysis in F5F8D, biochemical characterization of MCFD2-LMAN1 interaction, review of functional studies\",\n      \"journal\": \"British journal of haematology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — patient genetics combined with biochemical binding data; independently replicated across multiple labs\",\n      \"pmids\": [\"19183188\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"LMAN1-deficient mice show ~50% reduction in plasma FV and FVIII and platelet FV, confirming the ER-to-Golgi cargo receptor role of the LMAN1-MCFD2 complex for FV and FVIII; ER in Lman1-/- hepatocytes is distended with accumulation of α1-antitrypsin and GRP78, indicating ER stress.\",\n      \"method\": \"Mouse knockout model (Lman1-/- mice), plasma factor activity assays, electron microscopy, immunohistochemistry, in vitro COPII vesicle formation assay\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean knockout with specific phenotypic readout and multiple orthogonal assays\",\n      \"pmids\": [\"21795745\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Human mesenchymal stem cells (MSC) from lung, liver, brain, and bone marrow express FVIII mRNA and secrete functional FVIII protein; in MSC, FVIII localizes to the perinuclear region rather than being stored in granules, in contrast to endothelial cells.\",\n      \"method\": \"Quantitative RT-PCR, confocal microscopy with FVIII-specific antibody, aPTT and chromogenic functional assays of MSC supernatants and lysates\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct localization with functional confirmation; single lab study\",\n      \"pmids\": [\"23042590\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Regulated secretion of both VWF and FVIII from endothelial storage granules (Weibel-Palade bodies) occurs only when there is endogenous co-synthesis of FVIII together with VWF; VWF serves as the carrier protecting FVIII from proteolytic degradation in plasma.\",\n      \"method\": \"DDAVP stimulation experiments, cell biology studies of VWF/FVIII co-expression and co-storage\",\n      \"journal\": \"Pediatric blood & cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional co-secretion experiments with defined cellular readout; moderate evidence base\",\n      \"pmids\": [\"16470522\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"VWF inhibits uptake of FVIII by immature dendritic cells and activation of FVIII-specific T cells in a dose-dependent manner; recombinant VWF lacking the FVIII-binding domain did not inhibit T-cell activation, indicating that VWF reduces FVIII immunogenicity by shielding it from antigen-presenting cells through direct binding.\",\n      \"method\": \"In vitro dendritic cell uptake assay, T-cell activation assay with VWF and VWF mutant lacking FVIII-binding domain\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional assay with domain-deletion controls establishing mechanistic link; single lab\",\n      \"pmids\": [\"27587878\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"miR-374b-5p and miR-30c-5p target the 3'UTR of F8 mRNA; overexpression of these miRNAs in cell lines constitutively expressing FVIII decreased FVIII expression, while an miR-30c-5p inhibitor partially restored FVIII expression, establishing a miRNA-based mechanism for F8 gene regulation.\",\n      \"method\": \"miRNA sequencing, overexpression of miRNAs in FVIII-expressing cell lines, miRNA inhibitor experiments, FVIII activity assay\",\n      \"journal\": \"Transfusion\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — gain- and loss-of-function experiments with functional readout; single lab, moderate study size\",\n      \"pmids\": [\"31785023\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"miR-19b-3p and miR-186-5p directly interact with F8 mRNA (identified by RNA-affinity purification) and suppress FVIII protein levels when overexpressed in mammalian cells, providing further evidence that miRNAs targeting the F8 3'UTR can modulate FVIII production.\",\n      \"method\": \"In vivo RNA-affinity purification, miRNA overexpression in mammalian cells, FVIII activity measurement\",\n      \"journal\": \"Frontiers in cell and developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct RNA-affinity purification plus functional overexpression assay; single lab\",\n      \"pmids\": [\"32850803\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"LMAN1 primarily serves as a shuttling carrier for MCFD2, while MCFD2 carries out the actual cargo binding and transport of FV and FVIII; LMAN1 carbohydrate-binding activity is not essential for FV/FVIII transport; overexpression of MCFD2 alone is sufficient to rescue FV/FVIII secretion in LMAN1-deficient cells; the LMAN1-MCFD2 complex is not rate-limiting for ER-Golgi transport of FV/FVIII.\",\n      \"method\": \"LMAN1- and MCFD2-deficient cell lines (HEK293T, HepG2, HCT116), FV/FVIII secretion assays, rescue experiments with wild-type and mutant LMAN1/MCFD2 overexpression\",\n      \"journal\": \"Blood advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple cell-type knockouts with rescue experiments and mutant analysis; mechanistic dissection with orthogonal approaches\",\n      \"pmids\": [\"36490287\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Immune tolerance against FVIII is maintained by PD-L1-expressing regulatory T cells (Tregs) that ligate PD-1 on FVIII-specific B cells causing their apoptosis; FVIII-deficient mice lack such Tregs and develop inhibitors; repetitive FVIII injection (ITI) induces FVIII-specific PD-L1+ Tregs and re-engages B cell elimination; FVIII-specific Tregs exist in humans and upregulate PD-L1 after successful ITI.\",\n      \"method\": \"Mouse knockout model, flow cytometry, ITI mouse model, human patient samples, PD-1/PD-L1 blockade experiments, B cell apoptosis assays\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods in mouse and human, mechanistic pathway established with specific cellular readouts\",\n      \"pmids\": [\"36107620\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"A 23.4-kb tandem duplication of the proximal F8 gene (promoter, exon 1, and part of intron 1) causes markedly elevated FVIII levels (>400%) and familial thrombophilia; the duplication produces twofold upregulation of F8 mRNA; a 927-bp region within the duplicated F8 intron 1 contains an enhancer element driving >45-fold increased reporter activity in endothelial cells.\",\n      \"method\": \"Genetic analysis, quantitative RT-PCR, luciferase reporter assay in endothelial cells, chromatin accessibility analysis\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — reporter assay with functional validation of enhancer element, corroborated by patient genetics and RNA quantification\",\n      \"pmids\": [\"33275657\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"A single immunodominant HLA-DRA*01-DRB1*01:01-restricted epitope in FVIII (peptide 2194–2213, C2 domain) is recognized by CD4+ T-effector cells from both severe and mild hemophilia A subjects with inhibitors; high-avidity T-cell clones from multiple subjects share the same T-cell receptor beta (TCRB) gene, indicating a remarkably narrow TCR repertoire driving inhibitor responses.\",\n      \"method\": \"MHC class II tetramer staining, T-cell clone isolation, cytokine secretion assays, TCRB gene sequencing, high-throughput immunosequencing\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal immune assays including tetramers, clonal T-cell analysis, and high-throughput sequencing\",\n      \"pmids\": [\"27471234\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Amino acid substitution F2196A or M2199A within the immunodominant FVIII C2-domain epitope (residues 2194–2205) abrogates HLA-DRB1*01:01-restricted T-cell proliferation while retaining normal procoagulant activity and expression levels, establishing these residues as critical for MHC class II binding and T-cell recognition.\",\n      \"method\": \"Peptide-MHCII binding assays, T-cell proliferation assays with clones and polyclonal lines, production of recombinant BDD-FVIII mutant proteins with FVIII activity measurement\",\n      \"journal\": \"Blood advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis combined with functional MHCII binding, T-cell assay, and procoagulant activity measurement\",\n      \"pmids\": [\"29444872\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"A point mutation causing Leu176Pro substitution in the A1 domain of rat FVIII (F8 gene, autosomal chromosome 18 in rats) disrupts the tertiary structure of FVIII and causes hemophilia A-like FVIII deficiency; the defect is corrected by human plasma or recombinant human FVIII administration.\",\n      \"method\": \"F8 cDNA sequencing, coagulation factor activity assays, structural prediction, human FVIII replacement experiment in WAG/RijYcb rats\",\n      \"journal\": \"Journal of thrombosis and haemostasis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mutation identification with functional rescue; single study in a novel rat model\",\n      \"pmids\": [\"20626616\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"Factor VIII (F8) is a procofactor in blood coagulation that circulates as a metal ion-dependent (Ca2+, Cu2+) heterodimer of heavy and light chains in a noncovalent complex with von Willebrand factor (vWF); vWF binding requires sulfation of Tyr1680 and both the acidic region and C2 domain of the FVIII light chain, and protects FVIII from degradation; thrombin or factor Xa activate FVIII by cleaving at three defined sites (Arg372, Arg740 in heavy chain; Arg1689 in light chain) releasing it from vWF and generating factor VIIIa, which dramatically increases factor IXa catalytic efficiency (kcat) for factor X activation in the intrinsic tenase complex; APC inactivates FVIIIa by cleavage at Arg336 and Arg562 with consequent A2 domain dissociation; ER-to-Golgi secretion of FVIII requires the LMAN1-MCFD2 cargo receptor complex (MCFD2 mediates cargo binding while LMAN1 serves as the shuttling carrier); intron 22 inversions account for ~45% of severe hemophilia A; immune tolerance to FVIII is maintained by PD-L1+ regulatory T cells eliminating FVIII-specific B cells via PD-1 ligation; and miRNAs targeting the F8 3'UTR (including miR-374b-5p, miR-30c-5p, miR-19b-3p, miR-186-5p) can fine-tune FVIII protein levels.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"F8 encodes coagulation factor VIII (FVIII), a plasma procofactor essential for the intrinsic pathway of blood coagulation, whose deficiency causes hemophilia A. FVIII is synthesized in endothelial cells and other cell types, trafficked from the ER to the Golgi via the LMAN1–MCFD2 cargo receptor complex—where MCFD2 directly binds the cargo and LMAN1 serves as a membrane shuttle—and is stored in a regulated secretory pool only when co-synthesized with von Willebrand factor (VWF), which also shields FVIII from dendritic cell uptake and thereby limits its immunogenicity [PMID:19183188, PMID:36490287, PMID:16470522, PMID:18549909]. FVIII expression is controlled transcriptionally by an intronic enhancer element in intron 1 that is active in endothelial cells and post-transcriptionally by multiple miRNAs (miR-374b-5p, miR-30c-5p, miR-19b-3p, miR-186-5p) targeting the F8 3′UTR [PMID:33275657, PMID:31785023, PMID:32850803]. Immune tolerance to therapeutic FVIII is maintained by PD-L1-expressing regulatory T cells that induce apoptosis of FVIII-specific B cells via PD-1 ligation, and the dominant T-cell response to FVIII maps to an HLA-DRB1*01:01-restricted epitope in the C2 domain (residues 2194–2213), where substitutions at F2196 and M2199 abrogate immunogenicity without compromising procoagulant function [PMID:36107620, PMID:27471234, PMID:29444872].\",\n  \"teleology\": [\n    {\n      \"year\": 1987,\n      \"claim\": \"Mapping of FVIII inhibitor epitopes to specific polypeptide chains (92-kDa heavy chain and 80-kDa light chain) established that the anti-FVIII immune response is directed at discrete structural regions and is of restricted IgG subclass composition.\",\n      \"evidence\": \"Immunoblotting of purified FVIII with 76 inhibitor plasmas using anti-IgG subclass antibodies\",\n      \"pmids\": [\"2436689\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Fine epitope mapping within each chain not yet resolved\", \"No structural basis for epitope dominance\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Demonstration that regulated secretion of FVIII requires co-synthesis with VWF in endothelial cells resolved how FVIII enters a stimulated release pathway rather than being constitutively secreted.\",\n      \"evidence\": \"DDAVP-stimulated secretion assay in endothelial cells co-expressing FVIII and VWF\",\n      \"pmids\": [\"16470522\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Sorting signals directing FVIII to Weibel-Palade bodies not identified\", \"In vivo contribution of regulated vs. constitutive secretion not quantified\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"VWF was shown to reduce FVIII immunogenicity by physically blocking dendritic cell uptake of FVIII, requiring the VWF FVIII-binding domain, linking FVIII carrier function to immune evasion.\",\n      \"evidence\": \"In vitro dendritic cell uptake and T-cell activation assays with VWF domain-deletion constructs\",\n      \"pmids\": [\"18549909\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo relevance not demonstrated in this study\", \"Receptor mediating FVIII uptake on dendritic cells not identified\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Genetic and biochemical characterization of the LMAN1–MCFD2 complex as the cargo receptor for ER-to-Golgi transport of FVIII (and FV) resolved the molecular basis of combined F5F8 deficiency and implicated the B domain in cargo recognition.\",\n      \"evidence\": \"Genetic analysis of F5F8D patients, MCFD2 EF-hand mutagenesis, biochemical interaction studies\",\n      \"pmids\": [\"19183188\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct binding interface between MCFD2 and FVIII not structurally resolved\", \"Whether B domain is strictly required for transport not definitively shown\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Identification of a Leu176Pro missense mutation in the A1 domain as the cause of FVIII deficiency in WAG/RijYcb rats, correctable by human recombinant FVIII, validated the structural importance of the A1 domain for FVIII stability and provided a new animal model.\",\n      \"evidence\": \"F8 cDNA sequencing and phenotypic correction with recombinant FVIII in rats\",\n      \"pmids\": [\"20626616\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural mechanism of Leu176Pro destabilization not determined\", \"Single animal model, not replicated independently\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"LMAN1-knockout mice confirmed in vivo that LMAN1 is required for efficient FVIII (and FV) secretion, with ~50% reduction in plasma levels and ER distension in hepatocytes, establishing the physiological relevance of the LMAN1 cargo receptor pathway.\",\n      \"evidence\": \"Lman1-knockout mouse, plasma factor assays, COPII vesicle assay, electron microscopy\",\n      \"pmids\": [\"21795745\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Why residual ~50% FVIII secretion persists in LMAN1-null animals not explained\", \"Cell-type-specific contributions (hepatocyte vs. endothelial) not dissected\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Three concurrent advances refined FVIII biology: (1) splice-site mutations were shown to produce quantifiable residual wild-type transcript correlating with disease severity; (2) B-domain missense variants were functionally classified as non-pathogenic; (3) an immunodominant HLA-DRB1*01:01-restricted T-cell epitope was mapped to FVIII residues 2194–2213 with a restricted TCR repertoire.\",\n      \"evidence\": \"Quantitative RT-PCR of patient mRNA (splice mutations), COS-1 cell expression of B-domain variants, MHC class II tetramer staining and TCR sequencing of inhibitor patient T cells\",\n      \"pmids\": [\"25503412\", \"26915717\", \"27471234\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether the DRB1*01:01 epitope is dominant across all HLA alleles not established\", \"Functional dispensability of the B domain in vivo not confirmed\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Engineering deimmunized FVIII by substituting residues F2196 and M2199 within the immunodominant epitope abrogated T-cell recognition while preserving procoagulant activity, providing proof-of-concept for less immunogenic FVIII therapeutics.\",\n      \"evidence\": \"Peptide-MHCII binding, T-cell proliferation, and recombinant BDD-FVIII expression/activity assays\",\n      \"pmids\": [\"29444872\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo immunogenicity of deimmunized FVIII not tested\", \"Epitopes restricted by other common HLA alleles not addressed\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identification of miRNAs (miR-374b-5p, miR-30c-5p, miR-19b-3p, miR-186-5p) as post-transcriptional repressors of F8 via its 3′UTR established a new layer of FVIII expression regulation.\",\n      \"evidence\": \"miRNA overexpression/inhibition in FVIII-expressing cell lines, RNA-affinity purification\",\n      \"pmids\": [\"31785023\", \"32850803\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo relevance of miRNA regulation of FVIII levels not demonstrated\", \"Whether miRNA variation contributes to FVIII level heterogeneity in patients unknown\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"A 927-bp enhancer element in F8 intron 1 with >45-fold activity in endothelial cells was identified through a tandem duplication causing elevated FVIII, revealing a cis-regulatory mechanism for tissue-specific F8 transcription.\",\n      \"evidence\": \"Luciferase reporter assay in endothelial cells, chromatin accessibility analysis, qRT-PCR of duplication carriers\",\n      \"pmids\": [\"33275657\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Transcription factors binding the enhancer not identified\", \"Whether the enhancer is active in other FVIII-producing cell types unknown\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"The mechanism of peripheral immune tolerance to FVIII was shown to depend on PD-L1+ Tregs inducing apoptosis of FVIII-specific B cells via PD-1, with immune tolerance induction (ITI) restoring this pathway, directly linking Treg-mediated B-cell deletion to inhibitor resolution.\",\n      \"evidence\": \"FVIII-deficient mouse model with ITI, Treg transfer/depletion, PD-L1/PD-1 flow cytometry, apoptosis assays, human post-ITI sample analysis\",\n      \"pmids\": [\"36107620\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether additional tolerance mechanisms (anergy, receptor editing) contribute is not resolved\", \"Antigen-specificity of the PD-L1+ Tregs not fully characterized\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Reassignment of functional roles within the LMAN1–MCFD2 complex showed that MCFD2 is the direct cargo-binding subunit for FVIII/FV while LMAN1 functions as a membrane shuttle, overturning the model that LMAN1 lectin activity was essential for cargo selection.\",\n      \"evidence\": \"Rescue of FVIII/FV secretion by MCFD2 overexpression in LMAN1-deficient HEK293T, HepG2, and HCT116 cells\",\n      \"pmids\": [\"36490287\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How MCFD2 recognizes FVIII structurally remains unresolved\", \"Whether LMAN1-independent MCFD2 trafficking is physiologically relevant in vivo unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis of the MCFD2–FVIII interaction, the identity of transcription factors acting on the intron 1 enhancer, the in vivo significance of miRNA-mediated FVIII regulation, and whether deimmunized FVIII variants are non-immunogenic in animal models and patients.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of MCFD2-FVIII binding unknown\", \"Transcription factors at intron 1 enhancer unidentified\", \"In vivo validation of deimmunized FVIII lacking\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\n        \"term_id\": \"GO:0098772\",\n        \"supporting_discovery_ids\": [6, 8, 15]\n      }\n    ],\n    \"localization\": [\n      {\n        \"term_id\": \"GO:0005783\",\n        \"supporting_discovery_ids\": [0, 1, 2]\n      },\n      {\n        \"term_id\": \"GO:0005576\",\n        \"supporting_discovery_ids\": [3, 4, 13]\n      },\n      {\n        \"term_id\": \"GO:0031410\",\n        \"supporting_discovery_ids\": [3]\n      }\n    ],\n    \"pathway\": [\n      {\n        \"term_id\": \"R-HSA-109582\",\n        \"supporting_discovery_ids\": [6, 8, 15]\n      },\n      {\n        \"term_id\": \"R-HSA-168256\",\n        \"supporting_discovery_ids\": [4, 5, 6, 12, 13]\n      },\n      {\n        \"term_id\": \"R-HSA-9609507\",\n        \"supporting_discovery_ids\": [0, 1, 2]\n      }\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"VWF\",\n      \"LMAN1\",\n      \"MCFD2\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"Factor VIII (F8) is a plasma glycoprotein procofactor essential for the intrinsic pathway of blood coagulation, serving as the critical cofactor that dramatically increases the catalytic efficiency (kcat) of factor IXa for factor X activation within the intrinsic tenase complex [PMID:9834200, PMID:14684146]. FVIII circulates as a metal ion-dependent (Ca²⁺, Cu²⁺) heterodimer of heavy and light chains in a noncovalent complex with von Willebrand factor (vWF), which binds via the sulfated Tyr1680 residue and the C2 domain of the FVIII light chain and protects FVIII from proteolytic degradation and immune uptake [PMID:3134349, PMID:1898735, PMID:9218428, PMID:27587878]; thrombin or factor Xa activate FVIII by cleaving at Arg372, Arg740, and Arg1689, releasing it from vWF, while activated protein C inactivates FVIIIa by cleavage at Arg336 and Arg562 with consequent A2 domain dissociation [PMID:14684146, PMID:1939075]. ER-to-Golgi secretion of FVIII requires the LMAN1–MCFD2 cargo receptor complex, in which MCFD2 mediates direct cargo binding while LMAN1 serves as the shuttling carrier [PMID:12717434, PMID:36490287]. Loss-of-function mutations in F8—including intron 22 inversions accounting for ~45% of severe cases—cause hemophilia A, while immune tolerance to therapeutic FVIII is maintained by PD-L1⁺ regulatory T cells that eliminate FVIII-specific B cells via PD-1 ligation [PMID:8275087, PMID:36107620].\",\n  \"teleology\": [\n    {\n      \"year\": 1984,\n      \"claim\": \"Cloning the full-length F8 cDNA resolved the primary structure, domain architecture, and homology to factor V and ceruloplasmin, establishing the molecular identity of the coagulation cofactor and enabling recombinant expression that corrected hemophiliac plasma clotting.\",\n      \"evidence\": \"cDNA cloning, sequencing, and expression in mammalian cells with functional clotting assay\",\n      \"pmids\": [\"6438528\", \"6438526\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"B domain function remained unclear\", \"post-translational processing pathway not yet defined\"]\n    },\n    {\n      \"year\": 1985,\n      \"claim\": \"Identification of point mutations and deletions in the F8 gene as causes of hemophilia A established the heterogeneous mutational basis of the disease and linked genotype to phenotype.\",\n      \"evidence\": \"Southern blotting and direct sequencing in 92 hemophilia A patients\",\n      \"pmids\": [\"2987704\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"most common severe mutation (intron 22 inversion) not yet discovered\", \"genotype–phenotype correlations incomplete\"]\n    },\n    {\n      \"year\": 1991,\n      \"claim\": \"Defining the vWF-binding determinants on the FVIII light chain—particularly the essential role of sulfated Tyr1680 in the acidic region—and the APC inactivation sites (Arg336, Arg562) established the principal regulatory switches controlling FVIII stability and shutdown.\",\n      \"evidence\": \"Site-directed mutagenesis with COS-1 expression, vWF binding assays, and in vitro APC proteolysis with N-terminal sequencing of fragments\",\n      \"pmids\": [\"1898735\", \"1939075\", \"3134349\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"structural basis of A2 domain dissociation not determined\", \"relative contribution of C2 domain to vWF binding not yet quantified\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"Discovery that intrachromosomal inversions at intron 22 account for ~45% of severe hemophilia A identified the single most common causative mutation and transformed molecular diagnostics.\",\n      \"evidence\": \"Southern blot detection of inversion-specific restriction patterns in hemophilia A cohorts\",\n      \"pmids\": [\"8275087\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"mechanism favoring inversion in male meiosis not fully elucidated\", \"intron 1 inversions not yet characterized\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Demonstrating that both the acidic region and C2 domain contribute to high-affinity vWF binding refined the two-site model for the FVIII–vWF interaction.\",\n      \"evidence\": \"SPR binding kinetics of defined FVIII light chain fragments with vWF, monoclonal antibody competition\",\n      \"pmids\": [\"9218428\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"atomic-resolution structure of the FVIII–vWF interface not determined\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Kinetic characterization established that FVIIIa increases factor IXa activity primarily by elevating kcat rather than Km for factor X, defining the cofactor mechanism within the tenase complex.\",\n      \"evidence\": \"In vitro kinetic analysis of reconstituted tenase complex\",\n      \"pmids\": [\"9834200\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"structural basis of kcat enhancement by FVIIIa not resolved\", \"role of membrane surface in cofactor function incompletely defined\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Identification of MCFD2 mutations in combined FV/FVIII deficiency patients revealed that the LMAN1–MCFD2 complex functions as the ER-to-Golgi cargo receptor for FVIII (and FV), solving the secretion pathway question.\",\n      \"evidence\": \"Patient mutation analysis, co-immunoprecipitation, yeast two-hybrid, subcellular co-localization\",\n      \"pmids\": [\"12717434\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"relative contributions of LMAN1 vs MCFD2 to cargo binding not dissected\", \"whether the complex is rate-limiting for secretion unknown\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"The X-ray crystal structure of B domain-deleted FVIII revealed the spatial arrangement of the five domains with bound Ca²⁺ and Cu²⁺ ions, and in silico docking provided the first model of the FVIIIa–FIXa interface.\",\n      \"evidence\": \"X-ray crystallography of BDD-FVIII, computational docking with FIXa\",\n      \"pmids\": [\"18400180\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"no experimental structure of the FVIIIa–FIXa complex\", \"conformational changes upon thrombin activation not captured\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Identification of an immunodominant HLA-DRB1*01:01-restricted T-cell epitope in the FVIII C2 domain (residues 2194–2213) with a remarkably narrow TCR repertoire explained a key driver of inhibitor development, and subsequent mutagenesis showed that F2196A and M2199A abolish T-cell recognition while preserving procoagulant activity.\",\n      \"evidence\": \"MHC class II tetramer staining, T-cell cloning, TCR sequencing, peptide–MHCII binding assays, recombinant FVIII mutagenesis with activity measurement\",\n      \"pmids\": [\"27471234\", \"29444872\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"whether deimmunized FVIII variants are tolerated long-term in vivo not tested\", \"epitopes restricted by other HLA alleles not fully mapped\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Discovery that miRNAs (miR-374b-5p, miR-30c-5p, miR-19b-3p, miR-186-5p) target the F8 3′UTR and suppress FVIII production established a post-transcriptional regulatory layer for F8 gene expression.\",\n      \"evidence\": \"miRNA sequencing, gain- and loss-of-function experiments in FVIII-expressing cell lines, RNA-affinity purification\",\n      \"pmids\": [\"31785023\", \"32850803\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"physiological relevance of miRNA-mediated regulation of endogenous FVIII levels not demonstrated in vivo\", \"no reporter assay confirming direct 3′UTR interaction for all four miRNAs\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Demonstration that PD-L1⁺ Tregs eliminate FVIII-specific B cells via PD-1 ligation revealed the cellular mechanism maintaining peripheral tolerance to FVIII and explained why immune tolerance induction (ITI) can resolve inhibitors.\",\n      \"evidence\": \"Mouse knockout and ITI models, human patient samples, PD-1/PD-L1 blockade, B cell apoptosis assays, flow cytometry\",\n      \"pmids\": [\"36107620\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"whether PD-L1+ Treg mechanism applies across all HLA backgrounds not established\", \"signals driving PD-L1 upregulation on Tregs during ITI not identified\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identification of an endothelial-specific enhancer element within F8 intron 1 that drives markedly elevated FVIII levels when duplicated provided the first cis-regulatory explanation for familial thrombophilia due to FVIII excess.\",\n      \"evidence\": \"Genetic analysis of familial thrombophilia, quantitative RT-PCR, luciferase reporter assay in endothelial cells\",\n      \"pmids\": [\"33275657\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"transcription factors binding the enhancer element not identified\", \"chromatin context of enhancer activity in non-endothelial cells not explored\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Mechanistic dissection of the LMAN1–MCFD2 complex showed that MCFD2 performs direct cargo binding while LMAN1 serves as the cycling carrier, and that this complex is not rate-limiting for FVIII secretion, revising the earlier model.\",\n      \"evidence\": \"LMAN1- and MCFD2-deficient cell lines with rescue experiments and mutant LMAN1/MCFD2 overexpression across HEK293T, HepG2, and HCT116 cells\",\n      \"pmids\": [\"36490287\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"identity of the rate-limiting step in FVIII ER-to-Golgi transport remains unknown\", \"structural basis of MCFD2–FVIII interaction not determined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the atomic-resolution structure of the FVIIIa–FIXa tenase complex, the identity of transcription factors binding the intron 1 enhancer, the in vivo physiological relevance of miRNA regulation of FVIII levels, and whether deimmunized FVIII variants can achieve long-term tolerance in patients.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"no experimental FVIIIa–FIXa co-crystal or cryo-EM structure\", \"cis-regulatory architecture of the F8 locus incompletely defined\", \"clinical translation of deimmunized FVIII not tested\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [7, 9, 10]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [10]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 2, 7, 14]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [8, 11, 12, 18]},\n      {\"term_id\": \"GO:0005794\", \"supporting_discovery_ids\": [8, 11, 18]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [14]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-109582\", \"supporting_discovery_ids\": [0, 4, 7, 9, 10]},\n      {\"term_id\": \"R-HSA-9609507\", \"supporting_discovery_ids\": [8, 11, 12, 18]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [19, 21, 22]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [1, 5, 23]}\n    ],\n    \"complexes\": [\n      \"intrinsic tenase complex (FVIIIa–FIXa–FX)\",\n      \"FVIII–vWF complex\"\n    ],\n    \"partners\": [\n      \"VWF\",\n      \"F9\",\n      \"F10\",\n      \"LMAN1\",\n      \"MCFD2\",\n      \"PROC\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}